

Index to

VOLUME 16

***PHARMACOLOGY BIOCHEMISTRY
&
BEHAVIOR***

CONTENTS

Haloperidol-induced hyperactivity in neonatal rats: Effect of lithium and stimulants. SCHECHTER, M. D. and J. T. CONCANNON	1
Possible mechanism of 5-methoxy-N,N-dimethyltryptamine-induced turning behaviour in DRN lesioned rats. BLACKBURN, T. P., B. COX, C. G. HEAPY and T. F. LEE	7
Ethanol intoxication as a function of genotype dependent responses in three inbred mice strains. ELSTON, S. F. A., K. BLUM, L. DELALLO and A. H. BRIGGS	13
Differential effects of diazepam (Valium) on brain stimulation reward sites. CAUDARELLA, M., K. A. CAMPBELL and N. W. MILGRAM	17
Effects of intracerebroventricular capsaicin on thermoregulatory behavior in the rat. DIB, B.	23
Effect of benzodiazepines on cyclic GMP formation in rat cerebellar slices. SMITH, C. C., M. E. LEWIS and J. F. TALLMAN	29
Morphine withdrawal in mice selectively bred for differential sensitivity to ethanol. HOROWITZ, G. P. and A. M. ALLAN	35
Aggression induced by stimulation of the hypothalamus: Effects of androgens. BERMOND, B., J. MOS, W. MEELIS, A. M. VAN DER POEL and M. R. KRUK	41
The role of neurotransmitters in stress-induced antinociception (SIA). SNOW, A. E., S. M. TUCKER and W. L. DEWEY	47
Differential effects of LSD, serotonin and <i>l</i>-tryptophan on visually evoked responses. STRAHLENDORF, J. C. R., F. J. GOLDSTEIN, G. V. ROSSI and R. T. MALSEED	51
γ-Aminobutyric acid in brain areas of isolated aggressive or non-aggressive inbred strains of mice. SIMLER, S., S. PUGLISI-ALLEGRA and P. MANDEL	57
Drug-induced ataxia in opponents elicits "pathological" fighting in undrugged rats exposed to footshock. ELLIOTT, M. L. and R. J. SBORDONE	63
Failure to obtain functional equivalence between dopamine receptor blockade and extinction: Evidence supporting a sensory-motor conditioning hypothesis. TOMBAUGH, T. N., C. SZOSTAK, P. VOORNEVELD and J. W. TOMBAUGH	67
Effect of fusaric acid on aggression, motor activity, and brain monoamines in mice. DIRINGER, M. N., N. R. KRAMARCY, J. W. BROWN and J. B. THURMOND	73
Effects of parenteral morphine and oral methadone on self-stimulation in the rat. PRESHAW, R. L., H. ZENICK and R. M. STUTZ	81
Comparison of the suppression by naloxone of water intake induced in rats by hyperosmolarity, hypovolemia, and angiotensin. ROWLAND, N.	87
Modulation of food intake by hypothalamic implants of estradiol benzoate, estrone, estriol and CI-628 in female rats. DONOHOE, T. P. and R. STEVENS	93

Effects of hypothalamic knife cuts on feeding induced by paraventricular norepineprine injections. ARAVICH, P. F., A. SCLAFANI and S. F. LEIBOWITZ	101
Orally delivered pentobarbital as a reinforcer for rhesus monkeys with concurrent access to water: Effects of concentration, fixed-ratio size, and liquid positions. DENOBLE, V. J., D. S. SVIKIS and R. A. MEISCH	113
Interaction of opiates with dopamine receptors: Receptors binding and behavioral assays. CARLSON, K. R. and T. F. SEEGER	119
Different sensitivities to ethanol in alcohol-preferring and -nonpreferring rats. LUMENG, L., M. B. WALLER, W. J. McBRIDE and T. K. LI	125
Measurement of metabolites of dopamine and 5-hydroxytryptamine in cerebroventricular perfusates of unanesthetized, freely-moving rats: Selective effects of drugs. NIELSEN, J. A. and K. E. MOORE	131
Desglycyl-8-arginine vasopressin affects regional mouse brain cyclic AMP content. SCHNEIDER, D. R., B. T. FELT and H. GOLDMAN	139
Regional brain levels of monoamines in alcohol-preferring and -nonpreferring lines of rats. MURPHY, J. M., W. J. McBRIDE, L. LUMENG and T.-K. LI	145
Infant rat hyperactivity elicited by home cage bedding is unaffected by neonatal telencephalic dopamine or norepinephrine depletion. PAPPAS, B. A., G. VICKERS, M. BUXTON and W. PUSZTAY	151
Complete reversal of chronic ethanol polydipsia by schedule withdrawal. TANG, M., C. BROWN and J. L. FALK	155
Phencyclidine in combination with pentobarbital: Supra-additive effects on complex operant behavior in patas monkeys. THOMPSON, D. M. and J. M. MOERSCHBAECHER	159
Self-administration of nalbuphine, butorphanol and pentazocine by morphine post-addict rats. STEINFELS, G. F., G. A. YOUNG and N. KHAZAN	167
 <i>BRIEF COMMUNICATIONS</i>	
A temporal analysis of naloxone's suppressant effect on drinking. SIVIY, S. M., D. J. CALCAGNETTI and L. D. REID	173
Dissociation between behavioral and electrocortical manifestations of electroshock convulsions during the action of an anticonvulsive drug. DE-LA-CRUZ, F. and M. RUSSEK	177
Parameters of low-dose ethanol intravenous self-administration in the rat. SINDEN, J. D. and J. LE MAGNEN	181
DNA and protein synthesis in normal and transformed lymphocytes exposed to brain. BENNETT, C. E., A. B. GLASSMAN and M. WITTEN	185
 <i>ANNOUNCEMENTS</i>	 191

CONTENTS

The effect of DSP-4 on some positively reinforced operant behaviors in the rat. SPYRAKI, C., G. W. ARBUTHNOTT and H. C. FIBIGER	197
Development of serotonin-mediated behavioral inhibition in the hyperthyroid mouse. NAGY, Z. M. and M. J. FORSTER	203
The interaction of ethanol and swimming upon cardiac mass and mitochondrial function. FARRAR, R. P., C. M. ARDIES, R. L. SHOREY and C. K. ERICKSON	207
Dihydrotestosterone-induced inhibition of lordosis in estrogen-primed ovariectomized rats following 6-hydroxydopamine or electrolytic septal lesions. MENNITI, F. S., M. S. ERSKINE, S. A. TOBET and M. J. BAUM	211
Ontogenetic differences in response to d-amphetamine: Two-way avoidance, intertrial responses, and locomotor activity. BAUER, R. H.	217
Peptidergic regulation of norepinephrine induced feeding. MORLEY, J. E., A. S. LEVINE, S. S. MURRAY and J. KNEIP	225
MIF-1: Effects on norepinephrine, dopamine and serotonin metabolism in certain discrete brain regions. SINGHAL, R. L. and R. B. RASTOGI	229
The effect of drugs altering striatal dopamine levels on apomorphine induced stereotypy. FEIGENBAUM, J. J., J. YANAI, R. B. BLASS, B. MOON and H. KLAWANS	235
Analgesia induced by neonatal capsaicin treatment in rats. SAUMET, J.-L. and R. DUCLAUX	241
Photolabeling of benzodiazepine receptors spares [³ H]propyl β -carboline binding. HIRSCH, J. D.	245
D-Ala ² ,D-Leu ⁵ -enkephalin generalizes to a discriminative stimulus produced by fentanyl but not ethylketocyclazocine. SHEARMAN, G. T. and A. HERZ	249
Alcohol dependence and taste-mediated learning in the rat. CRAWFORD, D. and T. B. BAKER	253
Effects of chronic opiate administration on spontaneous activity of fetal rats. KIRBY, M. L. and S. G. HOLTZMAN	263
Interaction of methadone and pentobarbital on chained fixed-interval performance in pigeons. JENSEN, M. A. and T. THOMPSON	271
Chlordiazepoxide-induced released responding in extinction and punishment-conflict procedures is not altered by neonatal forebrain norepinephrine depletion. BIALIK, R. J., B. A. PAPPAS and W. PUSZTAY	279
Effects of estrogen on striatal dopamine receptor function in male and female rats. HRUSKA, R. E., L. M. LUDMER, K. T. PITMAN, M. DE RYCK and E. K. SILBERGELD	285
The dopaminergic mediation of a sweet reward in normal and VMH hyperphagic rats. XENAKIS, S. and A. SCLAFANI	293

Differential effects of amphetamine and fenfluramine on dietary self-selection in rats. ORTHEN-GAMBILL, N. and R. B. KANAREK	303
Circadian rhythm of brain susceptibility to haloperidol during chronic administration. NAGAYAMA, H., A. TAKAGI, S. YOSHIMOTO, H. MINAMI, K. NISHIWAKI and R. TAKAHASHI	311
Time-related differences in noradrenaline turnover in rat brain regions by stress. TANAKA, M., Y. KOHNO, R. NAKAGAWA, Y. IDA, S. TAKEDA and N. NAGASAKI	315
Is alcohol induced poikilothermia mediated by 5-HT and catecholamine receptors or by ionic set-point mechanism in the brain? MYERS, R. D. and W. D. RUWE	321
Amino acid neurotransmitter utilization in discrete rat brain regions is correlated with conditioned emotional response. LANE, J. D., M. P. SANDS, M. E. FREEMAN, D. R. CHEREK and J. E. SMITH	329
Hyperbaric ethanol antagonism: Role of temperature, blood and brain ethanol concentration. MALCOLM, R. D. and R. L. ALKANA	341
The effects of cocaine in a gustatory avoidance paradigm: A procedural analysis. FOLTIN, R. W. and C. R. SCHUSTER	347
 <i>BRIEF COMMUNICATIONS</i>	
A simple, inexpensive rotometer for automatically recording the dynamics of circling behavior. JERUSSI, T. P.	353
Cocaine increases isolation-induced fighting in mice. HADFIELD, M. G., E. A. NUGENT and D. E. W. MOTT	359
Pyridoxine reduces core body temperature in rats. LINDSETH, K. A. and R. A. HICKS	361
 <i>ANNOUNCEMENTS</i>	365

CONTENTS

Characteristics of Type 1 and Type 2 benzodiazepine receptors in the ovine brain. VILLIGER, J. W., K. M. TAYLOR and P. D. GLUCKMAN	373
Attention and habituation: Catecholamine interactions and sex differences. CHEAL, M. L.	377
Potency and duration of action of the ACTH 4-9 analog (ORG 2766) as compared to ACTH 4-10 and [D-Phe ⁷] ACTH 4-10 on active and passive avoidance behavior of rats. FEKETE, M. and D. DE WIED	387
Relative responding on concurrent schedules: Indexing ethanol's reinforcing efficacy. ROEHRS, T. A. and H. H. SAMSON	393
GABA mediation of the anti-aversive action of minor tranquilizers. BRANDÃO, M. L., J. C. DE AGUIAR and F. G. GRAEFF	397
Enhancement of stress-induced analgesia in adrenalectomized mice: Its reversal by dexamethasone. MAREK, P., I. PANOCKA and G. HARTMANN	403
Serotonin-induced gnawing in rats: Comparison with tail pinch-induced gnawing. LARSON, A. A. and M. H. KONZIELSKI	407
Neuroleptic and analgesic interactions upon pain and activity measures. BODNAR, R. J. and N. NICOTERA	411
Psychomotor stimulants, social deprivation and play in juvenile rats. BEATTY, W. W., A. M. DODGE, L. J. DODGE, K. WHITE and J. PANKSEPP	417
A comparison of the central and peripheral effects of atropine on force lever performance. PRESTON, K. L. and C. R. SCHUSTER	423
Lifetime monoamine oxidase inhibition and sleep. MENDELSON, W. B., R. M. COHEN, I. C. CAMPBELL, D. L. MURPHY, J. C. GILLIN and R. J. WYATT	429
Effects and interactions of naloxone and amphetamine on self-stimulation of the prefrontal cortex and dorsal tegmentum. FRANKLIN, K. B. J. and A. ROBERTSON	433
Multiple postsynaptic dopamine receptors and behavioral manifestation. FUJITA, N., A. HIRATA, K. SAITO and H. YOSHIDA	437
Age-dependent reduction in maximum electroshock convulsive threshold associated with decreased concentrations of brain monoamines. LONDON, E. D., S. B. WALLER, F. J. VOCCI and G. G. BUTERBAUGH	441
Specificity of the learned helplessness model of depression. SHERMAN, A. D., J. L. SACQUITNE and F. PETTY	449
Tactile extinction: Distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. SCHALLERT, T., M. UPCHURCH, N. LOBAUGH, S. B. FARRAR, W. W. SPIRDURO, P. GILLIAM, D. VAUGHN and R. E. WILCOX	455

Alleviation of anisomycin-induced amnesia by pre-test treatment with lysine-vasopressin. JUDGE, M. E. and D. QUARTERMAIN	463
Similar development of tolerance to barbitol-induced inhibition of avoidance behavior and loss of righting reflex in rats. RICHTER, J. A., P. S. HARRIS and P. V. HANFORD	467
Alcohol and morphine induced hypothermia in mice selected for sensitivity to ethanol. BRICK, J. and G. P. HOROWITZ	473
Pharmacological manipulation of milk-induced behaviors in three-day-old rat pups. CAZA, P. A. and L. P. SPEAR	481
Effects of profadol on operant behavior in the pigeon. LEANDER, J. D.	487
Behavioral pharmacology of local anesthetics: Reinforcing and discriminative stimulus effects. WOOLVERTON, W. L. and R. L. BALSTER	491
Induction of dependence on ethanol by free-choice drinking in alcohol-preferring rats. WALLER, M. B., W. J. McBRIDE, L. LUMENG and T.-K. LI	501
Brain neurotransmitter turnover correlated with morphine-seeking behavior of rats. SMITH, J. E., C. CO, M. E. FREEMAN and J. D. LANE	509
<i>BRIEF COMMUNICATION</i>	
Acute venous catheterization for integrated plasma sample collection in monkey. BREE, M. P., N. K. MELLO, K. L. HARVEY and S. A. WEBB	521
<i>ANNOUNCEMENTS</i>	525

CONTENTS

Benzodiazepines: Relationship between pharmacological activity in the rat and in vivo receptor binding. MENNINI, T., S. COTECCHIA, S. CACCIA and S. GARATTINI	529
Postnatal development of a cholinergic influence on neuroleptic-induced catalepsy. BURT, D. K., S. M. HUNGERFORD, M. L. CROWNER and L. A. BAEZ	533
Effect of haloperidol and chlorpromazine on reversal learning of normal and striatectomized rats in a Y-maze. ARUSHANIAN, E. B. and V. A. BATURIN	541
Effect of 6-hydroxydopamine-induced lesions of A10 dopaminergic neurons on aggressive behavior in rats. PUCIŁOWSKI, O., W. KOSTOWSKI, A. BIDZINSKI and M. HAUPTMANN ...	547
Discriminative stimulus properties of DOM and several molecular modifications. GLENNON, R. A., R. YOUNG and J. A. ROSECRANS	553
A comparison of the behavioral effects of DOM homologs. GLENNON, R. A., R. YOUNG and J. A. ROSECRANS	557
Effects of naloxone and naltrexone on locomotor activity in C57BL/6 and DBA/2 mice. CASTELLANO, C. and S. PUGLISI-ALLEGRA	561
Stereotyped behavior elicited by amphetamine in the rat: Influences of the testes. BEATTY, W. W., A. M. DODGE and K. L. TRAYLOR	565
The effects of methadone on the social behavior and activity of the rat. PLONSKY, M. and P. R. FREEMAN	569
Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. COLASANTI, B. K., C. LINDAMOOD, III and C. R. CRAIG	573
The effects of food deprivation and satiation on oral pentobarbital self-administration in rhesus monkeys. KLINER, D. J. and R. A. MEISCH	579
Long-term effects of fetal ethanol exposure on pituitary-adrenal response to stress. TAYLOR, A. N., B. J. BRANCH, S. H. LIU and N. KOKKA	585
Effect of diphenhydramine on stress-induced changes in brain histidine decarboxylase activity, histamine and plasma corticosterone levels. MAZURKIEWICZ-KWILECKI, I. M. and B. BIELKIEWICZ	591
Interaction of acute and chronic stress with respiration: Modification by naloxone. ISOM, G. E. and R. M. ELSHOWIHY	599
Effects of benactyzine on an equilibrium and multiple response task in rhesus monkeys. FARRER, D. N., M. G. YOCHMOWITZ, J. L. MATTSSON, N. E. LOF and C. T. BENNETT	605
Antibodies to GM1 ganglioside inhibit morphine analgesia. KARPIAK, S. E.	611
The ontogeny of spinal cord monoamines and the post-decapitation reflex. PAPPAS, B. A. and R. INGS	615

Antagonism of morphine-induced behavioral suppression by opiate receptor alkylators. MESSING, R. B., P. S. PORTOGHESE, A. E. TAKEMORI and S. B. SPARBER	621
Isoproterenol alters nonshivering thermogenesis in the Zucker obese rat (fafa). MILAM, K. M., J. S. STERN and B. A. HORWITZ	627
Effect of amphetamine and cocaine on seizure in lead treated mice. BURRIGHT, R. G., P. J. DONOVICK, K. MICHELS, R. J. FANELLI and Z. DOLINSKY	631
Psychological stress enhances noradrenaline turnover in specific brain regions in rats. IIMORI, K., M. TANAKA, Y. KOHNO, Y. IDA, R. NAKAGAWA, Y. HOAKI, A. TSUDA and N. NAGASAKI	637
Use of a single compartment LCEC cell in the determinations of biogenic amine content and turnover. CO, C., J. E. SMITH and J. D. LANE	641
Effects of chronic phencyclidine on fixed-ratio responding: Relation to neurotransmitter receptor binding in rat cerebral cortex. SCHWARTZ, R. D., J. M. MOERSCHBAECHER, D. M. THOMPSON and K. J. KELLAR	647
Opiate antagonists stimulate affiliative behaviour in monkeys. FABRE-NYS, C., R. E. MELLER and E. B. KEVERNE	653
Effects of pentobarbital and cocaine in rats expecting pentobarbital. HINSON, R. E., C. X. POULOS and H. CAPPELL	661
 BRIEF COMMUNICATION	
A comparison of the effects of pimozide and nonreinforcement on discriminated operant responding in rats. BENINGER, R. J.	667
 ANNOUNCEMENTS	671

CONTENTS

No evidence for cholinergic mechanisms in the control of spontaneous predatory behavior of the ferret. MEIERL, G. and W. J. SCHMIDT	677
Effects of morphine on fixed interval-induced escape from food reinforcement. SLIFER, B. E. ..	683
Convulsant benzodiazepine Ro 5-3663 has anxiolytic properties. FELDON, J. and M. MYSLOBODSKY	689
A new method for the determination of blood ethanol levels in rodents. POHORECKY, L. A. and J. BRICK	693
Influence of repeated deprivation upon starvation-induced hypovolemia and plasma aldosterone concentration in rats. WRIGHT, J. W. and E. M. SCHULZ	697
Dynorphin-(1-13), dopamine and feeding in rats. MORLEY, J. E., A. S. LEVINE, M. GRACE and J. KNEIP	701
Alcohol-morphine interactions: Oral intake in genetically selected Maudsley rats. SATINDER, K. P.	707
Effects of acute and daily cocaine administration on performance under a delayed-matching-to-sample procedure. BRANCH, M. N. and M. E. DEARING	713
Adrenal catecholamines in rats after severe ethanol intoxication and acute withdrawal. ADAMS, M. A., P. L. PURVIS and M. HIRST	719
Continuous infusion in rats as a method of assessing morphine-like physical dependence for opiates. McCARTHY, P. S., G. METCALF and S. J. HOWE	725
Prevention of reserpine rigidity by alpha-2 adrenergic antagonists. WAGNER, B. H. and R. J. ANDERSON	731
Rotation induced by intranigral phenobarbital: Evidence of barbiturate GABAergic activity. McDEVITT, J. T. and L. M. YUNGER	737
β -Adrenoceptor antagonists may attenuate hyponeophagia in the rat through a serotonergic mechanism. SHEPHARD, R. A., D. A. BUXTON and P. L. BROADHURST	741
Effects of caffeine on schedule-controlled responding in the rat. MELISKA, C. J. and R. E. BROWN	745
Opiate modification of amygdaloid-kindled seizures in rats. STONE, W. S., C. E. EGGLETON and R. F. BERMAN	751
Ethanol elimination rates in mice: Effects of gender, nutrition, and chronic ethanol treatment. ALLEN, D. L., R. G. LITTLE II, J. E. THEOTOKATOS and D. R. PETERSEN	757
Altered adult behavior of mice following postnatal treatment with haloperidol. DALLEMAGNE, G. and B. WEISS	761

Mitigation of the septal lesion syndrome by pre-lesion chronic treatment with haloperidol. MAROTTA, R. F., N. LOGAN, S. RIVERSO and E. L. GARDNER	769
Mechanisms of action of p-chlorophenylalanine in stimulating sexual receptivity in the female rat. WILSON, C. A., R. C. BONNEY, D. M. EVERARD, R. F. PARROTT and J. WISE	777
Effects of various catecholamine receptor antagonists, muscle relaxation and physical hindrance on shuttlebox self-stimulation. LIEBMAN, J. M., N. HALL and J. PROWSE	785
Differential effects of <i>d</i> -amphetamine, pipradrol and bupropion on shuttlebox self-stimulation. LIEBMAN, J. M., S. GERHARDT and J. PROWSE	791
Anxiolytic drugs selectively increase preferred duration of rewarding brain stimulation in a shuttlebox test. GERHARDT, S., J. PROWSE and J. M. LIEBMAN	795
Lithium toxicology: Effect of isotopic composition on lethality and behavior. ALEXANDER, G. J., K. W. LIEBERMAN, M. OKAMOTO, P. E. STOKES and E. TRIANA	801
Detection of cholinergic mediation of behavior in 7-, 9-, and 12-day old rat pups. SMITH, G. J., L. P. SPEAR and N. E. SPEAR	805
A comparison of the behavioral effects of proteo- and deuterio- <i>N,N</i> -dimethyltryptamine. BEATON, J. M., S. A. BARKER and W. F. LIU	811
Duration of response to pentobarbital of female vs male albino and pigmented rats. WESTENBERG, I. S. and J. M. BOLAM	815
Behavioral effects of intracerebroventricularly administered neurohypophyseal hormone analogs in mice. MEISENBERG, G. and W. H. SIMMONS	819
Naloxone alters alcohol drinking induced in the rat by tetrahydropapaveroline (THP) infused ICV. MYERS, R. D. and E. C. CRITCHER	827
 <i>BRIEF COMMUNICATIONS</i> 	
5 α -Androstane-3 β ,17 β -diol binds to androgen and estrogen receptors without activating copulatory behavior in female rats. DOERING, C. H. and B. A. GLADUE	837
Isolation rearing decreases opiate receptor binding in rat brain. SCHENK, S., M. D. BRITT, J. ATALAY and S. CHARLESON	841
Acute and chronic effects of phenytoin on fixed-ratio performance of pigeons. KRAFFT, K. and A. POLING	843
Effect of acute and chronic ethanol pre-treatment on the disposition of phencyclidine (PCP) in the rat. VADLAMANI, N. L., R. B. PONTANI and A. L. MISRA	847
Experimental studies of the abuse potential of <i>d,l</i> -glucine-1.5 phosphate in rhesus monkeys. SCHUSTER, C. R., T. AIGNER, C. E. JOHANSON and T. H. GIESKE	851
Effect of cocaine on afterdischarge threshold in previously kindled rats. STRIPLING, J. S. and C. HENDRICKS	855
Rate dependent inhibition of self-stimulation by apomorphine. CAREY, R. J.	859

CONTENTS

Selective action of morphine on reflex expression to nociceptive stimulation in the rat: A contribution to the assessment of analgesia. WARREN, P. H. and J. R. ISON 869

Influence of estrogen and progesterone on behavioral effects of apomorphine and amphetamine. MICHANEK, A. and B. J. MEYERSON 875

Forebrain serotonin and avoidance learning: Behavioural and biochemical studies on the acute effect of p-chloroamphetamine on one-way active avoidance learning in the male rat. ÖGREN, S. O. . . . 881

Peripherally administered somatostatin reduces feeding by a vagal mediated mechanism. LEVINE, A. S. and J. E. MORLEY 897

Does hypothermia play a relevant role in the glycemic alterations induced by ethanol? OLIVEIRA SOUZA, M. L. and J. MASUR 903

The effects of chronic administration of naltrexone on appetite and water exchange in rats. LANG, I. M., J. C. STRAHLENDORF, H. K. STRAHLENDORF, L. O. LUTHERER and C. D. BARNES 909

Lateralization of zinc in rat brain and its relationship to a spatial behavior. VALDES, J. J., S. W. HARTWELL, S. M. SATO and J. M. FRAZIER 915

Scopolamine does not disrupt spatial working memory in rats. GODDING, P. R., J. R. RUSH and W. W. BEATTY 919

Effect of methaqualone on plasma corticosterone in rats: Possible sites of action. BOGGAN, W. O. and J. S. MEYER 925

A study of the shaking and grooming induced by RX 336-M in rats. GMERER, D. E. and A. COWAN 929

Testosterone affects food intake and body weight by weanling male rats. NUNEZ, A. A. and M. GRUNDMAN 933

Phencyclidine retards autoshaping at a dose which does not suppress the required response. COVENEY, J. R. and S. B. SPARBER 937

Effects of TRH on acquisition and extinction of shuttlebox-avoidance behavior in Fischer₃₄₄ rats. TAMAKI, Y. and Y. KAMEYAMA 943

Increased fat consumption induced by morphine administration in rats. MARKS-KAUFMAN, R. 949

Pharmacologic control of pemoline induced self-injurious behavior in rats. MUELLER, K. and W. L. NYHAN 957

Animal model of depression: Pharmacological sensitivity of a hedonic deficit. KATZ, R. J. 965

A further parametric study of imipramine in an animal model of depression. KATZ, R. J. and G. BALDRIGHI 969

Animal model of depression: Tests of three structurally and pharmacologically novel antidepressant compounds. KATZ, R. J. and M. SIBEL	973
Further analysis of the specificity of a novel animal model of depression—effects of an antihistaminic, antipsychotic, and anxiolytic compound. KATZ, R. J. and M. SIBEL	979
Depression of learned thermoregulatory behavior by central injection of opioids in cats. CLARK, W. G. and G. L. BERNARDINI	983
Extreme hyperthermia induced in cats by the enkephalin analog FK 33-824. CLARK, W. G., G. L. BERNARDINI and S. W. PONDER	989
Alcohol drinking induced in the monkey by tetrahydropapaveroline (THP) infused into the cerebral ventricle. MYERS, R. D., M. L. McCALEB and W. D. RUWE	995
Naloxone suppresses insulin-induced food intake in novel and familiar environments, but does not affect hypoglycemia. ROWLAND, N. and T. J. BARTNESS	1001
Interaction of diazepam with meperidine or normeperidine on analgesia and lethality. LEANDER, J. D.	1005
Phencyclidine raises kindled seizure thresholds. FREEMAN, F. G., M. F. JARVIS and P. DUNCAN	1009
A comparison of the effects of opiate antagonists on operant and ingestive behavior. SANGER, D. J. and P. S. McCARTHY	1013
Effects of MIF-I, sex, and weight on tonic immobility in lizards (<i>Anolis carolinensis</i>). CASHNER, F. M., S. W. DELATTE, T. K. VON ALMEN, G. A. OLSON and R. D. OLSON ..	1017
INDEX TO VOLUME 16	1021

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 16 1982

SUBJECT INDEX

- Abrin, 185
DNA synthesis
human peripheral lymphocytes
protein synthesis
virus transformed lymphocytes
- Abstinence syndrome, 725
continuous infusion
dependence liability
narcotics
opiates
- Abuse potential, 851
d,l-glucine · 1.5 phosphate
rhesus monkeys
self-administration
- Acetylcholine, 533
catalepsy
dopamine
neuroleptics
postnatal development
- Acquisition, 943
avoidance
extinction
intertrial response
shuttlebox
TRH
- ACTH₄₋₁₀, 387
[D-Phe⁷]ACTH₄₋₁₀, potency and duration
active avoidance
ORG 2766, potency and duration
passive avoidance
- [D-Phe⁷]ACTH₄₋₁₀, potency and duration, 387
ACTH₄₋₁₀
active avoidance
ORG 2766, potency and duration
passive avoidance
- Active avoidance
ACTH₄₋₁₀, 387
[D-Phe⁷]ACTH₄₋₁₀, potency and duration, 387
anxiety, 467
anxiolytics, 467
barbital, 467
barbiturates, 467
brain drug levels, 467
central monoamines, 881
p-chloroamphetamine, 881
drug administration, chronic, 467
ORG 2766, potency and duration, 387
passive avoidance, 387
righting reflex, 467
serotonin release, 881
tolerance, 467
- Activity, 411
cold water swims
drug interaction
neuroleptics
opiate analgesia
pain
- Acute drug pretreatment, 847
chronic drug pretreatment
drug interaction
ethanol
phencyclidine
- Acute venous catheterization, 521
blood sample collection
integrated plasma sampling
primates
- Adrenal medulla, 719
catecholamines
ethanol
physical dependence
withdrawal syndrome
- Adrenalectomy, 403
analgesia
dexamethasone
pain
stress
- β -Adrenoceptor antagonists, 741
dopamine
hyponeophagia
5-MeODMT
neophobia
serotonin
- Afterdischarge threshold
amygdala, 1009
cocaine, 855
kindling, 1009
kindling, olfactory bulb, 855
phencyclidine, 1009
seizures, 1009
- Age differences, 217
amphetamine
avoidance
catecholamines
maturation
motor activity
- Aggression
androgens, 41
ataxia, 63
catecholamines, 359
cocaine, 359
dopaminergic system, 547
footshock, 63
hallucinogens, 63
hypothalamus, 41
isolation-induced, 359
lesions, 6-OHDA, 547
locomotor activity, 569
mesocorticolimbic system, 547
methadone, 569
muricide, 547

- social behavior, 569
- ventral mesencephalic tegmental area (nucleus A10), 547
- Aggressive behavior
 - brain monoamines, 73
 - dietary tyrosine, 73
 - fusaric acid, 73
 - GABA, 57
 - inbred mouse strains, 57
 - isolation, 57
 - mice, 73
 - motor activity, 73
- Albinism, 815
 - pentobarbital
 - response duration
 - sex differences
- Alcohol
 - amine-aldehyde condensation product, 827
 - calcium-sodium ratio, 321
 - dopamine, 321
 - drinking, 707, 827
 - drug interaction, 707
 - ethanol, 321
 - hypothermia, 321
 - Maudsley rats, 707
 - morphine, 707
 - naloxone, 827
 - norepinephrine, 321
 - opiate receptors, 827
 - poikilothermia, 321
 - salsolinol, 827
 - selective breeding, 707
 - serotonin (5-HT), 321
 - strain differences, 707
 - temperature set-point, 321
 - tetrahydropapaveroline, 827
 - thermoregulation, 321
- Alcohol dependence, 253
 - conditioned taste aversion
 - stress
 - withdrawal
- Alcohol-opiate commonalities, 35
 - ethanol sensitivity
 - morphine withdrawal
 - opiate dependence
- Alcohol preference
 - dopamine, 145
 - drinking, 501
 - ethanol concentration and distribution, 125
 - ethanol sensitivity, 125
 - free-choice alcohol consumption, 501
 - 5-hydroxyindoleacetic acid, 145
 - norepinephrine, 145
 - physical dependence, 501
 - regional brain monoamines, 145
 - selective breeding, 125, 501
 - serotonin, 145
 - withdrawal, 501
- Aldosterone, 697
 - angiotensin II
 - food deprivation
 - hypovolemia
 - plasma osmolality
 - sodium retention
- Alpha adrenergic antagonists, 731
 - alpha-2 receptors
 - autonomic responses
 - extrapyramidal effects
 - motor responses
 - reserpine rigidity
- Alpha-2 receptors, 731
 - alpha adrenergic antagonists
 - autonomic responses
 - extrapyramidal effects
 - motor responses
 - reserpine rigidity
- Ambient temperature, 903
 - blood glucose levels
 - body temperature
 - ethanol
 - hypothermia
 - tolerance
- Amine-aldehyde condensation product, 827
 - alcohol
 - drinking
 - naloxone
 - opiate receptors
 - salsolinol
 - tetrahydropapaveroline
- Amine-aldehyde metabolites, 995
 - drug interaction
 - ethanol self-selection
 - macaque monkey, female
 - route of delivery
 - tetrahydropapaveroline, ICV infusion
- Amnesia, 463
 - anisomycin
 - memory retrieval
 - passive avoidance
 - vasopressin
- Amphetamine
 - age differences, 217
 - animal models, hyperactivity, 1
 - anorexia, 303
 - apomorphine, 875
 - avoidance, 217
 - brain weight, 631
 - caloric intake, 303
 - carbohydrate, 303
 - castration, 565
 - catecholamines, 217
 - cocaine, 631
 - dietary self-selection, 303
 - dopaminergic supersensitivity, 1
 - dorsal tegmentum, 433
 - eating, 303
 - estrogen, 875
 - fat, 303
 - fenfluramine, 303
 - hyperactivity, haloperidol-induced, 1
 - lead acetate, 631
 - lithium, 1
 - maturation, 217
 - methylphenidate, 1
 - motor activity, 217
 - mouse genotype, 631
 - naloxone, 433
 - neonatal rats, 1
 - ovariectomy, 565
 - prefrontal cortex, 433
 - progesterone, 875
 - protein, 303
 - reward, 433
 - seizures, 631
 - self-stimulation, 433
 - sex differences, 565
 - sexual behavior, female rat, 875
 - stereotyped behavior, 565, 875
- d*-Amphetamine, 791
 - bupropion
 - pipradrol
 - self-stimulation
- Amygdala, 1009
 - afterdischarge thresholds
 - kindling
 - phencyclidine
 - seizures
- Analgesia
 - adrenalectomy, 403
 - antiganglioside serum, 611
 - capsaicin, 241

- choleragenoid, 611
- dexamethasone, 403
- diazepam, 1005
- drug interaction, 1005
- GM1 ganglioside, 611
- meperidine, 1005
- morphine, 869
- morphine receptors, 611
- neonatal treatment, 241
- nociceptive stimuli, 241, 869
- normeperidine, 1005
- opiates, 81
- pain, 403
- proconvulsive effects, 1005
- self-stimulation, 81
- startle reflex, 869
- stress, 403
- Androgen receptor, 837
 - 5 α -androstane-3 β ,17 β -diol
 - estrogen receptors
 - hypothalamic cytosol
 - lordosis
 - mounting behavior
 - ovariectomy
 - sexual behavior, female rat
- Androgens, 41
 - aggression
 - hypothalamus
- 5 α -Androstane-3 β ,17 β -diol, 837
 - androgen receptors
 - estrogen receptors
 - hypothalamic cytosol
 - lordosis
 - mounting behavior
 - ovariectomy
 - sexual behavior, female rat
- Anesthetics, local, 491
 - drug discrimination
 - reinforcement
 - self-administration
 - species differences
- Angiotensin II
 - aldosterone, 697
 - drinking, 87
 - food deprivation, 697
 - hyperosmolarity, 87
 - hypovolemia, 87, 697
 - naloxone, 87
 - opioids, 87
 - plasma osmolality, 697
 - sodium retention, 697
- Animal models, hyperactivity, 1
 - amphetamine
 - dopaminergic supersensitivity
 - hyperactivity, haloperidol-induced
 - lithium
 - methylphenidate
 - neonatal rats
- Anisomycin, 463
 - amnesia
 - memory retrieval
 - passive avoidance
 - vasopressin
- Anorexia, 303
 - amphetamine
 - caloric intake
 - carbohydrate
 - dietary self-selection
 - eating
 - fat
 - fenfluramine
 - protein
- Antiapomorphine effect, 311
 - chronic administration
 - circadian rhythm
- haloperidol
- Anticholinergic drugs, 919
 - memory, spatial
 - memory, working
 - scopolamine
- Anticonvulsants
 - convulsions, drug-induced, 177
 - convulsions, electroshock-induced, 177
 - electrocortical afterdischarges, 177
 - fixed-ratio schedule, 843
 - 5-OH-5-ethyl-5-phenyl-butiramide, 177
 - phenytoin, 843
 - pigeons, 843
 - tolerance, 843
- Antidepressants
 - anxiolytics, 449, 965
 - appetite, 965
 - buprion, 973
 - chronic stress, 965
 - defecation, 969
 - depressants, 449
 - depression, 449
 - depression, animal model, 965, 969, 973
 - electroconvulsive shock, 449
 - hedonic deficit, 965
 - imipramine, 965, 969
 - iprindole, 973
 - learned helplessness, 449
 - mianserine, 973
 - neuroleptics, 449
 - open field, 969
 - plasma corticosterone, 973
 - stimulants, 449
 - stress, 969, 973
- Antiganglioside serum, 611
 - analgesia
 - choleragenoid
 - GM1 ganglioside
 - morphine receptors
- Antihistamines, 979
 - anxiolytics
 - benzodiazepine
 - corticosterone
 - defecation
 - depression, animal model
 - haloperidol
 - neuroleptics
 - open field
 - oxazepam
 - tripelennamine
- Antileptazol, 529
 - anxiolytics
 - benzodiazepine receptors
 - camazepam
 - clobazam
 - diazepam binding
 - oxazepam
 - temazepam
- Antinociception, 47
 - dopamine
 - norepinephrine
 - serotonin
 - stress
 - tail-flick
- Anxiety
 - active avoidance, 467
 - anxiolytics, 467
 - barbital, 467
 - barbiturates, 467
 - brain drug levels, 467
 - chlordiazepoxide, 689
 - conditioned emotional response, 329
 - convulsant benzodiazepine, 689
 - drug administration, chronic, 467
 - GABA, 329, 689

- neurotransmitter metabolism, 329
- righting reflex, 467
- Ro 5-3663, 689
- shock history, 329
- stress, 329
- tolerance, 467
- Anxiolytics**
 - active avoidance, 467
 - antidepressants, 449, 965
 - antihistamines, 979
 - antileptazol, 529
 - anxiety, 467
 - appetite, 965
 - barbital, 467
 - barbiturates, 467
 - benzodiazepine, 979
 - benzodiazepine receptors, 529
 - brain drug levels, 467
 - camazepam, 529
 - chronic stress, 965
 - clobazam, 529
 - corticosterone, 979
 - defecation, 979
 - depressants, 449
 - depression, 449
 - depression, animal model, 965, 979
 - diazepam binding, 529
 - drug administration, chronic, 467
 - electroconvulsive shock, 449
 - haloperidol, 979
 - hedonic deficit, 965
 - imipramine, 965
 - learned helplessness, 449
 - neuroleptics, 449, 979
 - open field, 979
 - oxazepam, 529, 979
 - righting reflex, 467
 - stimulants, 449
 - temazepam, 529
 - tolerance, 467
 - tripelennamine, 979
- Apomorphine**
 - amphetamine, 875
 - dopamine, 859
 - dopaminergic agonists, 235
 - estrogen, 875
 - extinction, 859
 - progesterone, 875
 - self-stimulation, 859
 - sexual behavior, female rat, 875
 - stereotypy, 235, 859, 875
 - striatal dopamine receptors, 235
- Apparatus**
 - breath ethanol analyzer, 693
 - one compartment electrochemical detector cell, 641
 - primate equilibrium platform, 605
 - rotometer, 353
- Appetite**
 - antidepressants, 965
 - anxiolytics, 965
 - bicuculline, 225
 - bombesin, 225, 701
 - bromergocryptine, 701
 - calcitonin, 225
 - cholecystokinin octapeptide, 225, 701
 - chronic stress, 965
 - depression, animal model, 965
 - dopaminergic system, 701
 - drinking, 909
 - dynorphin, 701
 - eating, 225, 701, 909
 - hedonic deficit, 965
 - histidyl-proline diketopiperazine, 225
 - imipramine, 965
 - naltrexone, 225
 - naltrexone, 909
 - norepinephrine-induced feeding, 225
 - opiates, 701
 - renal electrolyte excretion, 909
 - renal water excretion, 909
 - satiety, 701
 - thyrotropin-releasing hormone, 225, 701
 - water exchange, 909
- Arecoline, 677**
 - central cholinergic mechanisms
 - ferret
 - nicotine
 - oxotremorine
 - predatory behavior
 - scopolamine
- Arousal, 929**
 - grooming
 - homeostasis
 - morphine withdrawal syndrome
 - RX 336-M
 - wet-dog shakes
- Aspartate, 509**
 - dopamine
 - GABA
 - glutamate
 - morphine self-administration
 - neurotransmitter turnover rates
 - norepinephrine
 - opiate reinforcement systems
 - serotonin
- Asymmetry, 455**
 - catecholamines
 - lesions, electrolytic
 - lesions, nigrostriatal
 - lesions, 6-OHDA
 - lesions, substantia nigra
 - sensorimotor dysfunction
 - sensory extinction
- Ataxia**
 - aggression, 63
 - behavioral toxicology, 801
 - footshock, 63
 - hallucinogens, 63
 - hypoactivity, 801
 - lethality, 801
 - lithium isotopes, 801
- Atropine methylnitrate, 423**
 - atropine sulfate
 - lever pressing
 - motor control
 - rhesus monkey
- Atropine sulfate, 423**
 - atropine methylnitrate
 - lever pressing
 - motor control
 - rhesus monkey
- Attention, 377**
 - catecholamine interactions
 - dopamine
 - gerbils
 - habituation
 - locomotor activity
 - norepinephrine
 - sex differences
- Automatic recording, 353**
 - circling behavior
 - rotometer
- Autonomic responses, 731**
 - alpha adrenergic antagonists
 - alpha-2 receptors
 - extrapyramidal effects
 - motor responses
 - reserpine rigidity
- Autoshaped behavior**
 - exploratory behavior, 937

- morphine-induced behavior suppression, 621
- opiate receptor alkylators, 621
- phencyclidine, 937
- Avoidance**
 - acquisition, 943
 - age differences, 217
 - amphetamine, 217
 - catecholamines, 217
 - extinction, 943
 - intertrial response, 943
 - maturation, 217
 - motor activity, 217
 - neuroleptics, 541
 - reversal learning, 541
 - shuttlebox, 943
 - spatial preference, 541
 - striatectomy, 541
 - TRH, 943
 - Y-maze performance, 541
- Avoidance training, 805**
 - cholinergic system
 - developmental psychopharmacology
 - response latency
 - scopolamine
- Barbital, 467**
 - active avoidance
 - anxiety
 - anxiolytics
 - barbiturates
 - brain drug levels
 - drug administration, chronic
 - righting reflex
 - tolerance
- Barbiturates**
 - active avoidance, 467
 - anxiety, 467
 - anxiolytics, 467
 - barbital, 467
 - brain drug levels, 467
 - drug administration, chronic, 467
 - GABA, 737
 - phenobarbital, 737
 - righting reflex, 467
 - rotation, 737
 - substantia nigra, 737
 - tolerance, 467
- Behavior disruption, 811**
 - kinetic isotope effect
 - proteo-N,N-dimethyltryptamine
 - tetradeutero-N,N-dimethyltryptamine
- Behavioral arousal, 667**
 - dopamine
 - extinction
 - multiple schedule
 - operant responding
 - pimozide
 - reinforcement
 - successive discrimination
- Behavioral effects, 819**
 - neurohypophyseal hormone analogs
 - oxytocin
 - structure-activity
 - vasopressin
- Behavioral efficacy, 841**
 - isolation rearing
 - opiates
 - receptor binding
- Behavioral tolerance, 647**
 - cerebral cortex
 - fixed-ratio responding
 - neurotransmitter receptor binding
 - phencyclidine
- Behavioral toxicology, 801**
 - ataxia
 - hypoactivity
 - lethality
 - lithium isotypes
- Benactyzine, 605**
 - operant behavior
 - primate equilibrium platform
 - rhesus monkey
- Benzodiazepine**
 - antihistamines, 979
 - anxiolytics, 979
 - benzodiazepine receptors, 29
 - corticosterone, 979
 - cyclic GMP, 29
 - defecation, 979
 - depression, animal model, 979
 - diazepam, 29
 - GABA, 29
 - haloperidol, 979
 - neuroleptics, 979
 - open field, 979
 - ouabain, 29
 - oxazepam, 979
 - tripelennamine, 979
- Benzodiazepine receptors**
 - antileptazol, 529
 - anxiolytics, 529
 - benzodiazepines, 29
 - brain, ovine, 373
 - camazepam, 529
 - clobazam, 529
 - cyclic GMP, 29
 - diazepam, 29, 245
 - diazepam binding, 529
 - ³H-diazepam binding, 373
 - GABA, 29
 - ligand binding, 245
 - multicomponent receptor, 245
 - ouabain, 29
 - oxazepam, 529
 - photoaffinity labeling, 245
 - propyl- β -carboline-3-carboxylate, 245
 - sparing from inactivation, 245
 - temazepam, 529
 - triazolopyridazine CL218,872, 373
- Bicuculline**
 - appetite, 225
 - bombesin, 225
 - calcitonin, 225
 - cholecystokinin octapeptide, 225
 - dorsal periaqueductal gray, 397
 - eating, 225
 - electrical stimulation, 397
 - flight behavior, 397
 - GABA mediation, 397
 - histidyl-proline diketopiperazine, 225
 - naloxone, 225
 - norepinephrine-induced feeding, 225
 - picrotoxin, 397
 - thyrotropin releasing hormone, 225
 - tranquilizers, 297
- Biogenic amine metabolites, 641**
 - biogenic monoamine turnover
 - dopamine
 - HPLC
 - norepinephrine
 - one compartment electrochemical detector cell
 - serotonin
- Biogenic monoamine turnover, 641**
 - biogenic amine metabolites
 - dopamine
 - HPLC
 - norepinephrine
 - one compartment electrochemical detector cell

- serotonin
- Blood ethanol, 693
 - breath ethanol analyzer
 - repeated sampling
- Blood glucose levels, 903
 - ambient temperature
 - body temperature
 - ethanol
 - hypothermia
 - tolerance
- Blood sample collection, 521
 - acute venous catheterization
 - integrated plasma sampling
 - primates
- Body temperature
 - ambient temperature, 903
 - blood glucose levels, 903
 - brain-blood ethanol, 341
 - capsaicin, 23
 - ethanol, 903
 - ethanol antagonists, 341
 - ethanol metabolism, 341
 - ethanol narcosis, 341
 - hyperbaric pressure, 341
 - hypothalamic temperature, 23
 - hypothermia, 903
 - thermoregulation, 23
 - tolerance, 903
- Body weight, 933
 - eating
 - prepubertal male rat
 - testosterone
- Bombesin
 - appetite, 225, 701
 - bicuculline, 225
 - bromergocryptine, 701
 - calcitonin, 225
 - cholecystokinin octapeptide, 225, 701
 - dopaminergic system, 701
 - dynorphin, 701
 - eating, 225, 701
 - histidyl-proline diketopiperazine, 225
 - naloxone, 225
 - norepinephrine-induced feeding, 225
 - opiates, 701
 - satiety, 701
 - thyrotropin-releasing hormone, 225, 701
- Brain
 - adrenal cortex, 403
 - adrenal medulla, 719
 - amygdala, 57, 315, 637, 751, 1009
 - capsaicin, 23
 - caudate nucleus, 509
 - central periaqueductal gray, 433
 - cerebellum, 29, 245, 373, 529
 - cerebral cortex, 145, 229, 315, 637, 647, 881
 - cerebral ventricle, 131
 - corpus striatum, 145, 915
 - cortex, 591, 915
 - dorsal periaqueductal gray, 397
 - dorsal raphe, 7
 - dorsal tegmentum, 433
 - frontal cortex, 139, 373
 - globus pallidus, 509
 - hippocampus, 17, 145, 139, 245, 315, 373, 881, 915
 - hypothalamus, 17, 23, 41, 145, 229, 315, 585, 591, 637, 837, 881
 - lateral cerebral ventricle, 995
 - lateral hypothalamus, 433
 - locus coeruleus, 615
 - medial forebrain bundle, 7
 - medulla oblongata, 315
 - medulla-pons, 139
 - mesolimbic area, 119
 - midbrain, 591, 881
 - neostriatum, 151
 - nigrostriatum, 455
 - nucleus accumbens septi, 211
 - occipital cortex, 139
 - olfactory bulb, 57, 139, 855
 - olfactory tubercles, 229
 - paraventricular hypothalamic nucleus, 101
 - parietal cortex, 139, 373
 - pars reticulata, 737
 - periaqueductal gray, 611
 - pituitary, 585
 - pons, 315
 - pons-medulla, 145, 229, 637
 - posterior colliculus, 57
 - prefrontal cortex, 433
 - putamen, 509
 - raphe nucleus, 51
 - septum, 57, 139, 211, 769
 - spinal cord, 881
 - striatum, 57, 119, 139, 229, 235, 245, 285, 373, 541, 881
 - substantia nigra, 455, 737
 - temporal cortex, 373
 - thalamus, 139, 145, 315
 - ventral mesencephalic tegmental area (nucleus A10), 547
 - ventromedial hypothalamus, 93, 293
- Brain-blood ethanol, 341
 - body temperature
 - ethanol antagonists
 - ethanol metabolism
 - ethanol narcosis
 - hyperbaric pressure
- Brain drug levels, 467
 - active avoidance
 - anxiety
 - anxiolytics
 - barbital
 - barbiturates
 - drug administration, chronic
 - righting reflex
 - tolerance
- Brain monoamines, 73
 - aggressive behavior
 - dietary tyrosine
 - fusaric acid
 - mice
 - motor activity
- Brain, mouse, 139
 - cyclic AMP
 - vasopressin
- Brain, ovine, 373
 - benzodiazepine receptors
 - ³H-diazepam binding
 - triazolopyridazine CL218,872
- Brain perfusion, 131
 - dihydroxyphenylacetic acid
 - endogenous dopamine metabolites
 - homovanillic acid
 - HPLC
 - 5-hydroxyindoleacetic acid
- Brain region differences
 - footshock, 637
 - MHPG-SO₄, 315, 637
 - noradrenaline turnover, 315, 637
 - plasma corticosterone, 315
 - stress, 637
 - stress, immobilization, 315
 - time-related differences
- Brain weight, 631
 - amphetamine
 - cocaine
 - lead acetate
 - mouse genotype
 - seizures
- Breath ethanol analyzer, 693
 - blood ethanol
 - repeated sampling

- Bromergocryptine, 701
 - appetite
 - bombesin
 - cholecystokinin octapeptide
 - dopaminergic system
 - dynorphin
 - eating
 - opiates
 - satiety
 - thyrotropin-releasing hormone
- Brown adipose tissue, 627
 - isoproterenol
 - obesity
 - thermogenesis
 - Zucker rats
- Buprion, 973
 - antidepressants
 - depression, animal model
 - iprindole
 - mianserine
 - plasma corticosterone
 - stress
- Bupropion, 791
 - d*-amphetamine
 - pipradrol
 - self-stimulation
- Butorphanol, 167
 - drug self-administration
 - morphine-dependent rats
 - nalbuphine
 - pentazocine
 - physical dependence

- Caffeine, 745
 - rate-dependency
 - schedule-controlled responding
 - time course
- Calcitonin, 225
 - appetite
 - bicuculline
 - bombesin
 - cholecystokinin octapeptide
 - eating
 - histidyl-proline diketopiperazine
 - naloxone
 - norepinephrine-induced feeding
 - thyrotropin releasing hormone
- Calcium-sodium ratio, 321
 - alcohol
 - dopamine
 - ethanol
 - hypothermia
 - norepinephrine
 - poikilothermia
 - serotonin (5-HT)
 - temperature set-point
 - thermoregulation
- Caloric intake, 303
 - amphetamine
 - anorexia
 - carbohydrate
 - dietary self-selection
 - eating
 - fat
 - fenfluramine
 - protein
- Caloric intake patterns, 949
 - carbohydrate
 - dietary self-selection
 - eating
 - β -endorphin
 - fat
 - morphine
 - protein
- Camazepam, 529
 - antileptazol
 - anxiolytics
 - benzodiazepine receptors
 - clobazam
 - diazepam binding
 - oxazepam
 - temazepam
- Capsaicin
 - analgesia, 241
 - body temperature, 23
 - hypothalamic temperature, 23
 - neonatal treatment, 241
 - nociceptive stimuli, 241
 - thermoregulation, 23
- Carbohydrate
 - amphetamine, 303
 - anorexia, 303
 - caloric intake, 303
 - caloric intake patterns, 949
 - dietary self-selection, 303, 949
 - eating, 303, 949
 - β -endorphin, 949
 - fat, 303, 949
 - fenfluramine, 303
 - morphine, 949
 - protein, 303, 949
- Cardiac mass, 207
 - ethanol
 - mitochondrial function
 - swimming
- Castration, 565
 - amphetamine
 - ovariectomy
 - sex differences
 - stereotyped behavior
- Catalepsy, 533
 - acetylcholine
 - dopamine
 - neuroleptics
 - postnatal development
- Catecholamine interactions, 377
 - attention
 - dopamine
 - gerbils
 - habituation
 - locomotor activity
 - norepinephrine
 - sex differences
- Catecholamines
 - adrenal medulla, 719
 - age differences, 217
 - aggression, isolation-induced, 359
 - amphetamine, 217
 - asymmetry, 455
 - avoidance, 217
 - cocaine, 359
 - convulsions, tonic, 441
 - development, 441
 - electroshock, 441
 - ethanol, 719
 - isolation, 417
 - lesions, electrolytic, 455
 - lesions, nigrostriatal, 455
 - lesions, 6-OHDA, 455
 - lesions, substantia nigra, 455
 - maturation, 217
 - monoamines, 441
 - motor activity, 217
 - physical dependence, 719
 - play, 417
 - psychomotor stimulants, 417
 - sensorimotor dysfunction, 455
 - sensory extinction, 455

- serotonin, 441
- social behavior, 417
- withdrawal syndrome, 719
- Cats, 51
 - hallucinogens
 - LSD
 - serotonin (5-HT)
 - l-tryptophan
 - visual evoked responses
- Central cholinergic mechanisms, 677
 - arecoline
 - ferret
 - nicotine
 - oxotremorine
 - predatory behavior
 - scopolamine
- Central monoamines, 881
 - active avoidance
 - p-chloroamphetamine
 - serotonin release
- Central reward mechanisms, 1013
 - drinking
 - eating
 - naloxone
 - naltrexone
 - operant behavior
 - opiate antagonists
- Cerebral asymmetry, 915
 - copper
 - hippocampus
 - lateralization
 - spatial behavior
 - zinc
- Cerebral cortex, 647
 - behavioral tolerance
 - fixed-ratio responding
 - neurotransmitter receptor binding
 - phencyclidine
- Chained schedule, 271
 - drug interactions
 - fixed interval
 - methadone
 - pentobarbital
 - pigeons
- Chlordiazepoxide
 - anxiety, 689
 - CL218,872, 795
 - conflict, 795
 - convulsant benzodiazepine, 689
 - diazepam, 795
 - extinction, 279
 - GABA, 689
 - 6-hydroxydopamine, neonatal, 279
 - norepinephrine depletion, 279
 - pentobarbital, 795
 - punishment-conflict, 279
 - Ro 5-3663, 689
 - self-stimulation, 795
 - shuttlebox, 795
- p-Chloroamphetamine
 - active avoidance, 881
 - central monoamines, 881
 - p-chlorophenylalanine, 957
 - diazepam, 957
 - dopaminergic mechanisms, 957
 - haloperidol, 957
 - pemoline, 957
 - pimozide, 957
 - self-injury, 957
 - serotonin release, 881
- p-Chlorophenylalanine
 - p-chloroamphetamine, 957
 - diazepam, 957
 - dopaminergic mechanisms, 957
 - haloperidol, 957
- 5-hydroxytryptophan, 777
- lordosis, 777
- noradrenaline, 777
- pemoline, 957
- pimozide, 957
- self-injury, 957
- serotonin, 777
- sexual behavior, female rat, 777
- Cholecystokinin octapeptide (CCK-8)
 - appetite, 225, 701
 - bicuculline, 225
 - bombesin, 225, 701
 - bromergocryptine, 701
 - calcitonin, 225
 - dopaminergic system, 701
 - dynorphin, 701
 - eating, 225, 701
 - histidyl-proline diketopiperazine, 225
 - naloxone, 225
 - norepinephrine-induced feeding, 225
 - opiates, 701
 - satiety, 701
 - thyrotropin releasing hormone, 225, 701
- Cholera toxin, 611
 - analgesia
 - antiganglioside serum
 - GM1 ganglioside
 - morphine receptors
- Cholinergic system, 805
 - avoidance training
 - developmental psychopharmacology
 - response latency
 - scopolamine
- Chronic administration, 311
 - antiapomorphine effect
 - circadian rhythm
 - haloperidol
- Chronic drug pretreatment, 847
 - acute drug pretreatment
 - drug interaction
 - ethanol
 - phencyclidine
- Chronic ethanol intake, 155
 - drinking
 - overdrinking
 - schedule-induced polydipsia
- Chronic opiate administration, 263
 - hyperactivity
 - hypoactivity
 - in utero* studies, rats
 - morphine tolerance
 - spontaneous activity, fetal rat
 - withdrawal
- Chronic stress, 965
 - antidepressants
 - anxiolytics
 - appetite
 - depression, animal model
 - hedonic deficit
 - imipramine
- Chronic treatment, 757
 - ethanol dependence
 - ethanol elimination rates
 - gender differences
- Circadian rhythm, 311
 - antiapomorphine effect
 - chronic administration
 - haloperidol
- Circling behavior, 353
 - automatic recording
 - rotometer
- CL218,872, 795
 - chlordiazepoxide
 - conflict
 - diazepam

- pentobarbital
 - self-stimulation
 - shuttlebox
- Clobazam, 529
 - antileptazol
 - anxiolytics
 - benzodiazepine receptors
 - camazepam
 - diazepam binding
 - oxazepam
 - temazepam
- Clonidine, 785
 - clozapine
 - haloperidol
 - methocarbamol
 - metoclopramide
 - prazosin
 - self-stimulation
 - shuttlebox
- Clorgyline, 429
 - drug administration, "lifetime"
 - drug administration, subacute
 - monoamine oxidase
 - REM sleep
 - sleep stages
- Clozapine, 785
 - clonidine
 - haloperidol
 - methocarbamol
 - metoclopramide
 - prazosin
 - self-stimulation
 - shuttlebox
- Cobalt epilepsy, 573
 - marijuana cannabinoids
 - REM sleep
 - seizures, epileptic
 - tetrahydrocannabinols
- Cocaine
 - afterdischarge threshold, 855
 - aggression, isolation-induced, 359
 - amphetamine, 631
 - brain weight, 631
 - catecholamines, 359
 - conditional discrimination, 713
 - conditional drug states, 661
 - conditioned taste aversion, 347
 - cross-potentialion, 661
 - kindling, olfactory bulb, 855
 - lead acetate, 631
 - matching-to-sample, 713
 - memory, 713
 - mouse genotype, 631
 - Pavlovian conditioning, 661
 - pentobarbital, 661
 - pigeons, 713
 - seizures, 631
 - tolerance, 661, 713
- Cold water swims, 411
 - activity
 - drug interaction
 - neuroleptics
 - opiate analgesia
 - pain
- Concurrent schedules
 - drinking, 113, 393
 - drug concentration, 113
 - drug self-administration, oral, 113
 - ethanol, 393
 - fixed ratio schedules, 113
 - pentobarbital reinforcement, 113
 - reinforcement, 393
 - relative responding, 393
 - rhesus monkeys, 113
 - water intake, 113
- Conditional discrimination, 713
 - cocaine
 - matching-to-sample
 - memory
 - pigeons
 - tolerance
- Conditional drug states, 661
 - cocaine
 - cross-potentialion
 - Pavlovian conditioning
 - pentobarbital
 - tolerance
- Conditioned emotional response, 329
 - anxiety
 - GABA
 - neurotransmitter metabolism
 - shock history
 - stress
- Conditioned taste aversion
 - alcohol dependence, 253
 - cocaine, 253, 347
 - stress, 253
 - withdrawal, 253
- Conflict, 795
 - chlordiazepoxide
 - CL218,872
 - diazepam
 - pentobarbital
 - self-stimulation
 - shuttlebox
- Continuous infusion, 725
 - abstinence syndrome
 - dependence liability
 - narcotics
 - opiates
- Contralateral turning behavior, 7
 - dopaminergic system
 - dorsal raphe lesion
 - 5-HT receptor
 - 5-methoxy-N,N-dimethyltryptamine
- Convulsant benzodiazepine, 689
 - anxiety
 - chlordiazepoxide
 - GABA
 - Ro 5-3663
- Convulsions, drug-induced, 177
 - anticonvulsants
 - electrocortical afterdischarges
 - electroshock-induced
 - 5-OH-5-ethyl-5-phenyl-butiramide
- Convulsions, electroshock-induced, 177
 - anticonvulsants
 - drug-induced
 - electrocortical afterdischarges
 - 5-OH-5-ethyl-5-phenyl-butiramide
- Convulsions, tonic, 441
 - catecholamines
 - development
 - electroshock
 - monoamines
 - serotonin
- Copper, 915
 - cerebral asymmetry
 - hippocampus
 - lateralization
 - spatial behavior
 - zinc
- Corticosterone
 - antihistamines, 979
 - anxiolytics, 979
 - benzodiazepine, 979
 - defecation, 979
 - depression, animal model, 979
 - fetal ethanol, 585
 - haloperidol, 979

- hypothalamic-pituitary-adrenal system, 585
- neuroleptics, 979
- open field, 979
- oxazepam, 979
- prenatal ethanol, 585
- stress, 585
- tripelennamine, 979
- Cross-potential, 661
 - cocaine
 - conditional drug states
 - Pavlovian conditioning
 - pentobarbital
 - tolerance
- Cyclic AMP, 139
 - brain, mouse
 - vasopressin
- Cyclic GMP, 29
 - benzodiazepine receptors
 - benzodiazepines
 - diazepam
 - GABA
 - ouabain
- Defecation
 - antidepressants, 969
 - antihistamines, 979
 - anxiolytics, 979
 - benzodiazepine, 979
 - corticosterone, 979
 - depression, animal model, 969, 979
 - haloperidol, 979
 - imipramine, 969
 - neuroleptics, 979
 - open field, 969, 979
 - oxazepam, 979
 - stress, 969
 - tripelennamine, 979
- Dependence liability, 725
 - abstinence syndrome
 - continuous infusion
 - narcotics
 - opiates
- Depressants, 449
 - antidepressants
 - anxiolytics
 - depression
 - electroconvulsive shock
 - learned helplessness
 - neuroleptics
 - stimulants
- Depression, 449
 - antidepressants
 - anxiolytics
 - depressants
 - electroconvulsive shock
 - learned helplessness
 - neuroleptics
 - stimulants
- Depression, animal model
 - antidepressants, 965, 969, 973, 979
 - antihistamines, 979
 - anxiolytics, 965, 979
 - appetite, 965
 - benzodiazepine, 979
 - buprion, 973
 - chronic stress, 965
 - corticosterone, 979
 - defecation, 969, 979
 - haloperidol, 979
 - hedonic deficit, 965
 - imipramine, 965, 969
 - iprindole, 973
 - mianserine, 973
 - neuroleptics, 979
 - open field, 969, 979
 - oxazepam, 979
 - plasma corticosterone, 973
 - stress, 969, 973
 - tripelennamine, 979
- Development
 - catecholamines, 441
 - convulsions, tonic, 441
 - electroshock, 441
 - haloperidol, 761
 - monoamines, 441
 - operant conditioning, 761
 - postnatal treatment, 761
 - serotonin, 441
 - spontaneous activity, 761
- Developmental psychopharmacology, 805
 - avoidance training
 - cholinergic system
 - response latency
 - scopolamine
- Dexamethasone, 403
 - adrenalectomy
 - analgesia
 - pain
 - stress
- Diazepam
 - analgesia, 1005
 - benzodiazepines, 29
 - chlordiazepoxide, 795
 - p-chloroamphetamine, 957
 - p-chlorophenylalanine, 957
 - CL218,872, 795
 - conflict, 795
 - cyclic GMP, 29
 - dopaminergic mechanisms, 957
 - drug interaction, 1005
 - GABA, 29
 - haloperidol, 957
 - hippocampus, 17
 - hypothalamus, 17
 - ligand binding, 245
 - meperidine, 1005
 - multicomponent receptor, 245
 - normeperidine, 1005
 - ouabain, 29
 - pemoline, 957
 - pentobarbital, 795
 - photoaffinity labeling, 245
 - pimozide, 957
 - proconvulsive effects, 1005
 - propyl- β -carboline-3-carboxylate, 245
 - self-biting, 957
 - self-stimulation, 17, 795
 - shuttlebox, 795
 - sparing from inactivation, 245
- Diazepam binding
 - antileptazol, 529
 - anxiolytics, 529
 - benzodiazepine receptors, 29, 245, 529
 - camazepam, 529
 - clobazam, 529
 - oxazepam, 529
 - temazepam, 529
- ³H-Diazepam binding
 - benzodiazepine receptors, 373
 - brain, ovine, 373
 - triazolopyridazine CL218,872, 373
- Dietary self-selection
 - amphetamine, 303
 - anorexia, 303
 - caloric intake, 303
 - caloric intake patterns, 949
 - carbohydrate, 303, 949
 - eating, 303, 949

- β -endorphin, 949
- fat, 303, 949
- fenfluramine, 303
- morphine, 949
- protein, 303, 949
- Dietary tyrosine, 73
 - aggressive behavior
 - brain monoamines
 - fusaric acid
 - mice
 - motor activity
- 5- α -Dihydrotestosterone, 211
 - estrogen
 - lesions, electrolytic
 - lesions, 6-OHDA
 - lesions, septal nuclei
 - lordosis
 - mesolimbic dopamine pathway
 - ovariectomy
 - sexual behavior, female rat
- Dihydroxyphenylacetic acid, 131
 - brain perfusion
 - endogenous dopamine metabolites
 - HPLC
 - homovanillic acid
 - 5-hydroxyindoleacetic acid
- 2,5-Dimethoxy-4-methylphenylisopropylamine (DOM)
 - discriminative stimulus properties, 553, 557
 - 2,5-DMA, 553
 - DOM homologs, 557
 - DOM molecular modifications, 553
 - hallucinogens, 553, 557
- 2,5-Dimethoxyphenylisopropylamine (2,5-DMA), 553
 - discriminative stimulus properties
 - DOM
 - DOM molecular modification
 - hallucinogens
- Diphenhydramine, 591
 - histamine levels
 - histidine decarboxylase
 - plasma corticosterone
 - stress
- Discriminative stimulus properties
 - 2,5-DMA, 553
 - DOM, 553, 557
 - DOM homologs, 557
 - DOM molecular modifications, 553
 - hallucinogens, 553, 557
- DNA synthesis, 185
 - abrin
 - human peripheral lymphocytes
 - protein synthesis
 - virus transformed lymphocytes
- DOM homologs, 557
 - discriminative stimulus properties
 - DOM
 - hallucinogens
- DOM molecular modifications, 553
 - discriminative stimulus properties
 - 2,5-DMA
 - DOM
 - hallucinogens
- Dopamine
 - acetylcholine, 533
 - β -adrenoceptor antagonists, 741
 - alcohol, 321
 - alcohol preference, rats, 145
 - antinociception, 47
 - apomorphine, 859
 - aspartate, 509
 - attention, 377
 - behavioral arousal, 667
 - biogenic amine metabolites, 641
 - biogenic monoamine turnover, 641
 - calcium-sodium ratio, 321
 - catalepsy, 533
 - catecholamine interactions, 377
 - dopamine, 145, 321
 - extinction, 667, 859
 - GABA, 509
 - gerbils, 377
 - glutamate, 509
 - gnawing, 407
 - habituation, 377
 - HPLC, 641
 - 5-hydroxyindoleacetic acid, 145
 - hyponeophagia, 741
 - hypothermia, 321
 - intrathecal injections, 407
 - locomotor activity, 377
 - 5-MeODMT, 741
 - morphine self-administration, 509
 - multiple schedule, 667
 - neophobia, 741
 - neuroleptics, 533
 - neurotransmitter turnover rates, 509
 - norepinephrine, 47, 145, 321, 377, 509, 641
 - one compartment electrochemical detector cell, 641
 - operant responding, 667
 - opiate reinforcement systems, 509
 - pimozide, 667
 - poikilothermia, 321
 - postnatal development, 533
 - regional brain monoamines, 145
 - reinforcement, 667
 - self-stimulation, 859
 - serotonin (5-HT), 47, 145, 407, 509, 641, 741
 - sex differences, 377
 - stereotypy, 859
 - stress, 47
 - successive discrimination, 667
 - tail-flick, 47
 - tail-pinch, 407
 - temperature set-point, 321
 - thermoregulation, 321
- Dopamine depletion, 151
 - environmental differences
 - hyperactivity
 - neonatal catecholamines
 - norepinephrine depletion
- Dopamine metabolism, 229
 - homovanillic acid
 - MIF-1
 - norepinephrine metabolism
 - serotonin metabolism
 - striatum
 - tyrosine hydroxylase
- Dopamine receptors
 - estrogen, 285
 - estrous cycle, female rat, 285
 - hypersensitivity, 119
 - locomotor activity, 119
 - mesolimbic area, 119
 - neuroleptics, 119
 - opiates, 119
 - rotational behavior, 437
 - 3 H-spiroperidol binding, 119
 - stereotyped behavior, 119, 285, 437
 - striatum, 119, 285
- Dopamine receptor blockade, 67
 - extinction
 - pimozide
 - sensory-motor conditioning hypothesis
- Dopamine theory of reward, 293
 - finickiness
 - hyperphagia
 - lesion, hypothalamic
 - licking behavior
 - pimozide
 - quinine

- sweet reward
- Dopaminergic agonists, 235
 - apomorphine
 - stereotypy
 - striatal dopamine receptors
- Dopaminergic mechanisms, 957
 - p-chloroamphetamine
 - p-chlorophenylalanine
 - diazepam
 - haloperidol
 - pemoline
 - pimozide
 - self-injury
- Dopaminergic supersensitivity, 1
 - amphetamine
 - animal models, hyperactivity
 - hyperactivity, haloperidol-induced
 - lithium
 - methylphenidate
 - neonatal rats
- Dopaminergic system
 - aggression, 547
 - appetite, 701
 - bombesin, 701
 - bromergocryptine, 701
 - cholecystokinin octapeptide, 701
 - contralateral turning behavior, 7
 - dorsal raphe lesion, 7
 - dynorphin, 701
 - eating, 701
 - 5-HT receptor, 7
 - lesions, 6-OHDA, 547
 - mesocorticolimbic system, 547
 - 5-methoxy-N,N-dimethyltryptamine, 7
 - muricide, 547
 - opiates, 701
 - satiety, 701
 - thyrotropin-releasing hormone, 701
 - ventral mesencephalic tegmental area (nucleus A10), 547
- Dorsal periaqueductal gray, 397
 - bicuculline
 - electrical stimulation
 - flight behavior
 - GABA mediation
 - picrotoxin
 - tranquilizers
- Dorsal raphe lesion, 7
 - contralateral turning behavior
 - dopaminergic system
 - 5-HT receptor
 - 5-methoxy-N,N-dimethyltryptamine
- Dorsal tegmentum, 433
 - amphetamine
 - naloxone
 - prefrontal cortex
 - reward
 - self-stimulation
- Drinking
 - alcohol, 707, 827
 - alcohol preference, 501
 - amine-aldehyde condensation product, 827
 - angiotensin II, 87
 - appetite, 909
 - central reward mechanisms, 1013
 - chronic ethanol intake, 155
 - concurrent schedules, 113, 393
 - drug concentration, 113
 - drug interaction, 707
 - drug self-administration, oral, 113
 - eating, 909, 1013
 - endorphins, 173
 - ethanol, 393
 - fixed ratio schedules, 113
 - free-choice alcohol consumption, 501
 - hyperosmolarity, 87
 - hypovolemia, 87
 - Maudsley rats, 707
 - morphine, 707
 - naloxone, 87, 173, 827, 1013
 - naltrexone, 909, 1013
 - operant behavior, 1013
 - opiate antagonists, 1013
 - opiate receptors, 827
 - opioids, 87
 - overdrinking, 155
 - pentobarbital reinforcement, 113
 - physical dependence, 501
 - reinforcement, 393
 - relative responding, 393
 - renal electrolyte excretion, 909
 - renal water excretion, 909
 - rhesus monkeys, 113
 - salsolinol, 827
 - schedule-induced polydipsia, 155
 - selective breeding, 501, 707
 - strain differences, 707
 - tetrahydropapaveroline, 827
 - water exchange, 909
 - water intake, 113
 - withdrawal, 501
- Drug
 - abrin, 185
 - alcohol, 253, 321, 707, 827
 - amitriptyline, 449
 - amphetamine, 1, 217, 235, 303, 417, 449, 565, 621, 631
 - d-amphetamine, 433, 491, 791, 875
 - l-amphetamine, 433, 875
 - anisomycin, 463
 - antiganglioside serum, 611
 - antileptazol, 529
 - apomorphine, 47, 119, 131, 235, 377, 437, 859, 875
 - arecoline, 677
 - atenolol, 741
 - atropine, 533
 - atropine methylnitrate, 423
 - atropine sulfate, 423
 - barbital, 467
 - BC105, 47
 - benactyzine, 605
 - benzodiazepine, 373, 529, 689, 979
 - bicuculline, 225, 397
 - bromergocryptine, 701
 - bupropion, 791, 973
 - butaclamol, 321
 - butorphanol, 167
 - caffeine, 449, 745
 - camazepam, 529
 - capsaicin, 241
 - carbachol, 397
 - propyl- β -carboline-3-carboxylate, 245
 - chlordiazepoxide, 279, 397, 449, 689, 795
 - β -chlornaltrexamine, 621
 - p-chloroamphetamine, 441, 881, 957
 - p-chlorophenylalanine, 777, 957
 - chlorprocaine, 491
 - chlorpromazine, 411, 449, 541, 615
 - cholera toxin, 611
 - cinanserin, 7, 51
 - CL218,872, 795
 - clobazam, 529
 - clonidine, 47, 377, 731, 785
 - clorgyline, 429
 - clozapine, 533, 785
 - cocaine, 347, 359, 491, 631, 661, 713, 855
 - codeine, 851
 - corticosterone, 979
 - cypheptadine, 7
 - desipramine, 449, 881
 - desmethylimipramine, 377
 - dexamethasone, 403, 585

dextrorphan, 263
diazepam, 17, 29, 245, 329, 449, 529, 795, 957, 1005
³H-diazepam, 373
L-dihydroxyphenylalanine, 441
5,7-dihydroxytryptamine, 441
dimethocaine, 491
dimethylaminoethanol (Deanol), 491
dimethylprocaine, 491
diphenhydramine, 591
2,5-DMA, 553
DOM, 553, 557
doxepin, 449
DSP-4, 197
dynorphin, 897
D-Ala², D-Leu⁵-enkephalin, 249
ethanol, 13, 35, 63, 125, 155, 181, 207, 321, 341, 393, 449, 473, 501, 585, 693, 719, 757, 903, 995
ethylketocyclazocine, 249
fenfluramine, 303
fentanyl, 249
fluoxetine, 881
β-fumarate methyl naltrexone, 621
fusaric acid, 73
d,l-glucine · 1.5 phosphate, 851
2-deoxy-D-glucose, 411
haloperidol, 1, 7, 47, 131, 311, 407, 411, 449, 541, 701, 761, 769, 785, 957, 979
histidyl-proline diketopiperazine, 225
γ-hydroxybutyrate, 235
6-hydroxydopamine, 151, 441, 455, 615
5-hydroxytryptophan, 441, 777
hyoscine, 7
imipramine, 449, 965, 969
iprindole, 449, 973
iproniazid, 449
isoproterenol, 627
LSD, 51, 63
lead acetate, 631
levorphanol, 263
lisuride hydrogen maleate, 437
lithium, 1
lithium chloride, 801
lorazepam, 449
marijuana, 573
meperidine, 1005
mescaline, 63
metergoline, 881
methadone, 81, 119, 271, 569
methaqualone, 925
methiothepin, 481
methocarbamol, 785
5-methoxy N,N-dimethyltryptamine (5-MeODMT), 7, 741
3-methoxy-4-hydroxyphenylethyleneglycol sulfate (MHPG-SO₄), 637
α-methyl-p-tyrosine, 7, 235
methylphenidate, 1, 417
methysergide, 7, 203, 321, 407, 481, 731, 741
metoclopramide, 785
mianserin, 449, 973
morphine, 35, 81, 119, 167, 263, 411, 473, 487, 509, 611, 621, 683, 707, 725, 751, 869, 949, 983
muscimol, 897
nalbuphine, 167
naloxone, 7, 35, 87, 173, 225, 263, 407, 433, 473, 487, 561, 599, 653, 701, 725, 751, 827, 989, 1001, 1013
naltrexone, 561, 653, 751, 909, 1013
nicotine, 677
nitromifene citrate (CI-628), 93
norepinephrine, 101, 225, 897
normeperidine, 1005
nortryptiline, 449
5-OH-5-ethyl-5-phenyl-butiramide, 377
6-OHDA, 547
ouabain, 29
oxazepam, 529, 979
oxotremorine, 677
pargyline, 131, 449
pemoline, 957
pentazocine, 167, 983
pentobarbital, 63, 113, 159, 271, 397, 487, 579, 661, 795, 815
phencyclidine, 159, 647, 847, 937, 1009
phenobarbital, 449, 737
phenoxybenzamine, 47, 615
phenolamine, 321, 481, 731
phenytoin, 843
picrotoxin, 7, 397, 737
pimozide, 67, 293, 667, 975
pindolol, 741
piperocaine, 491
pipradrol, 791
prazosin, 615, 785
probenecid, 131
procainamide, 491
procaine, 491
profadol, 487
propoxycaine, 491
propranolol, 481, 471
proteo-N,N-dimethyltryptamine, 811
pyridoxine, 361
quinine, 293
quipazine, 47, 481
reserpine, 731
Ro 5-3663, 689
RX 336-M, 929
salsolinol, 827
scopolamine, 481, 677, 805, 919
serotonin, 51, 407
SKF-7265, 731
spiroperidol, 533
strychnine, 7, 397
sulpiride, 437, 653
temazepam, 529
tetrabenazine, 441
tetradentoro-N,N-dimethyltryptamine, 811
Δ⁸-tetrahydrocannabinol, 573
Δ⁹-tetrahydrocannabinol, 573
tetrahydropapaveroline, 827, 995
thyroxine, 203
triazolopyridazine, CL218,872, 373
tripelennamine, 979
l-tryptophan, 51, 131
L-tyrosine, 73
xylamidine, 7
yohimbine, 615, 731
zimelidine, 881
Drug administration, chronic, 467
active avoidance
anxiety
anxiolytics
barbital
barbiturates
brain drug levels
righting reflex
tolerance
Drug administration, "lifetime", 429
clorgyline
drug administration, subacute
monoamine oxidase
REM sleep
sleep stages
Drug administration, subacute, 429
clorgyline
drug administration, "lifetime"
monoamine oxidase
REM sleep
sleep stages
Drug concentration, 113
concurrent schedules
drinking
drug self-administration, oral

- fixed ratio schedules
- pentobarbital reinforcement
- rhesus monkeys
- water intake
- Drug discrimination
 - anesthetics, local, 491
 - D-Ala², D-Leu⁵-enkephalin, 249
 - ethylketocyclazocine, 249
 - fentanyl, 249
 - multiple opiate receptors, 249
 - narcotics, 249
 - reinforcement, 491
 - self-administration, 491
 - species differences, 491
- Drug interactions
 - activity, 411
 - acute drug pretreatment, 847
 - alcohol, 707
 - amine-aldehyde metabolites, 995
 - analgesia, 1005
 - chained schedule, 271
 - chronic drug pretreatment, 847
 - cold water swims, 411
 - diazepam, 1005
 - drinking, 707
 - ethanol, 847
 - ethanol self-selection, 995
 - ethanol sensitivity, 473
 - fixed interval, 271
 - hypothermia, 473
 - macaque monkey, female, 995
 - Maudsley rats, 707
 - meperidine, 1005
 - methadone, 271
 - morphine, 473, 707
 - multiple schedule, 159
 - neuroleptics, 411
 - normeperidine, 1005
 - operant behavior, 159
 - opiate analgesia, 411
 - opiates, 473
 - pain, 411
 - patas monkeys, 159
 - pentobarbital, 159, 271
 - pharmacogenetics, 473
 - phencyclidine, 159, 847
 - pigeons, 271
 - preconvulsive effects, 1005
 - response chains, 159
 - route of delivery, 995
 - selective breeding, 473, 707
 - strain difference, 707
 - supra-additive effects, 159
 - tetrahydropapaveroline, ICV infusion, 995
- Drug self-administration
 - butorphanol, 167
 - concurrent schedules, 113
 - drinking, 113
 - drug concentration, 113
 - ethanol, 181
 - fixed ratio schedules, 113
 - morphine-dependent rats, 167
 - nalbuphine, 167
 - pentazocine, 167
 - pentobarbital reinforcement, 113
 - physical dependence, 167
 - reward, 181
 - rhesus monkeys, 113
 - water intake, 113
- DSP-4, 197
 - noradrenaline
 - operant behavior
 - positive reinforcement
- Dynorphin, 701
 - appetite

- bombesin
- bromergocryptine
- cholecystokinin octapeptide
- dopaminergic system
- eating
- opiates
- satiety
- thyrotropin-releasing hormone

Eating

- amphetamine, 303
- anorexia, 303
- appetite, 225, 303, 909
- bicuculline, 225
- body weight, 933
- bombesin, 225, 701
- bromergocryptine, 701
- calcitonin, 225
- caloric intake, 303
- caloric intake patterns, 949
- carbohydrate, 303, 949
- central reward mechanisms 1013
- cholecystokinin octapeptide, 225, 701
- dietary self-selection, 303, 949
- dopaminergic system, 701
- drinking, 909, 1013
- dynorphin, 701
- β -endorphin, 949
- estrogen and food intake, 93
- fat, 303, 949
- fenfluramine, 303
- food deprivation, 579
- histidyl-proline diketopiperazine, 225
- hypoglycemia, 1001
- hypothalamic hyperphagia, 101
- insulin-induced feeding, 1001
- knife cuts, hypothalamus, 101
- morphine, 949
- naloxone, 225, 1001, 1013
- naltrexone, 909, 1013
- nitromifene citrate (CI-628), 93
- noradrenergic feeding, 101
- norepinephrine, 101
- norepinephrine-induced feeding, 225
- novel environment, 1001
- obesity, 101
- operant behavior, 1013
- opiate antagonists, 1013
- opiates, 701
- pentobarbital, 579
- prepubertal male rat, 933
- protein, 303, 949
- renal electrolyte excretion, 909
- renal water excretion, 909
- rhesus monkeys, 579
- satiety, 579, 701, 897
- self-administration, oral, 579
- somatostatin, 897
- testosterone, 933
- thyrotropin releasing hormone, 225, 701
- vagus nerve, 897
- ventromedial hypothalamus, 93
- water exchange, 909
- Electrical stimulation, 397
 - bicuculline
 - dorsal periaqueductal gray
 - flight behavior
 - GABA mediation
 - picrotoxin
 - tranquilizers
- Electrocortical afterdischarges, 177
 - anticonvulsants
 - convulsions, drug-induced
 - convulsions, electroshock-induced

5-OH-5-ethyl-5-phenyl-butiramide
 Electroconvulsive shock, 455
 antidepressants
 anxiolytics
 depressants
 depression
 learned helplessness
 neuroleptics
 stimulants
 Electroshock, 441
 catecholamines
 convulsions, tonic
 development
 monoamines
 serotonin
 Emotionality, 769
 haloperidol
 hyperirritability
 lesions, septal
 recovery of function
 septal rage
 Endogenous dopamine metabolites, 131
 brain perfusion
 dihydroxyphenylacetic acid
 homovanillic acid
 HPLC
 5-hydroxyindoleacetic acid
 β -Endorphin, 949
 caloric intake patterns
 carbohydrate
 dietary self-selection
 eating
 fat
 morphine
 protein
 Endorphins
 drinking, 173
 naloxone, 173, 599
 respiration, 599
 stress, 599
 D-Ala²,D-Leu⁵-enkephalin, 249
 drug discrimination
 ethylketocyclazocine
 fentanyl
 multiple opiate receptors
 narcotics
 Environmental differences, 151
 dopamine depletion
 hyperactivity
 neonatal catecholamines
 norepinephrine depletion
 Estrogen
 amphetamine, 875
 apomorphine, 875
 5 α -dihydrotestosterone, 211
 dopamine receptors, 285
 estrous cycle, female rat, 285
 lesions, electrolytic, 211
 lesions, 6-OHDA, 211
 lesions, septal nuclei, 211
 lordosis, 211
 mesolimbic dopamine pathway, 211
 ovariectomy, 211
 progesterone, 875
 sexual behavior, female rat, 211, 875
 stereotyped behavior, 875
 stereotypy, 285
 striatum, 285
 Estrogen and food intake, 93
 eating
 nitromifene citrate (CI-628)
 ventromedial hypothalamus
 Estrogen receptors, 837
 androgen receptors
 5 α -androstane-3 β ,17 β -diol
 hypothalamic cytosol
 lordosis
 mounting behavior
 ovariectomy
 sexual behavior, female rat
 Estrous cycle, female rat, 285
 dopamine receptors
 estrogen
 stereotypy
 striatum
 Ethanol
 acute drug pretreatment, 847
 adrenal medulla, 719
 alcohol, 321
 ambient temperature, 903
 blood glucose levels, 903
 body temperature, 903
 calcium-sodium ratio, 321
 cardiac mass, 207
 catecholamines, 719
 chronic drug pretreatment, 847
 concurrent schedules, 393
 drinking, 393
 dopamine, 321
 drug interaction, 847
 drug self-administration, 181
 hypothermia, 321, 903
 mitochondrial function, 207
 norepinephrine, 321
 phencyclidine, 847
 physical dependence, 719
 poikilothermia, 321
 reinforcement, 393
 relative responding, 393
 reward, 181
 serotonin (5-HT), 321
 swimming, 207
 temperature set-point, 321
 thermoregulation, 321
 tolerance, 903
 withdrawal syndrome, 719
 Ethanol antagonists, 341
 body temperature
 brain-blood ethanol
 ethanol metabolism
 ethanol narcosis
 hyperbaric pressure
 Ethanol concentration and distribution, 125
 alcohol preference
 ethanol sensitivity
 selective breeding
 Ethanol dependence, 757
 chronic treatment
 ethanol elimination rates
 gender differences
 Ethanol elimination rates, 757
 chronic treatment
 ethanol dependence
 gender differences
 Ethanol intoxication, 13
 ethanol sensitivity
 genotypic responses
 inbred mice
 Ethanol metabolism, 341
 body temperature
 brain-blood ethanol
 ethanol antagonists
 ethanol narcosis
 hyperbaric pressure
 Ethanol narcosis, 341
 body temperature
 brain-blood ethanol
 ethanol antagonists
 ethanol metabolism
 hyperbaric pressure

- Ethanol self-selection, 995
 - amine-aldehyde metabolites
 - drug interaction
 - macaque monkey, female
 - route of delivery
 - tetrahydropapaveroline, ICV infusion
- Ethanol sensitivity
 - alcohol-opiate commonalities, 35
 - alcohol preference, 125
 - drug interactions, 473
 - ethanol concentration and distribution, 125
 - ethanol intoxication, 13
 - genotypic responses, 13
 - hypothermia, 473
 - inbred mice, 13
 - morphine, 473
 - morphine withdrawal, 35
 - opiates, 473
 - opiate dependence, 35
 - pharmacogenetics, 473
 - selective breeding, 35, 473
- Ethylketocyclazocine, 249
 - drug discrimination
 - D-Ala²,D-Leu⁵-enkephalin
 - fentanyl
 - multiple opiate receptors
 - narcotics
- Exploratory behavior, 937
 - autoshaping
 - phencyclidine
- Extrapyramidal effects, 731
 - alpha adrenergic antagonists
 - alpha-2 receptors
 - autonomic responses
 - motor responses
 - reserpine rigidity
- Extinction
 - acquisition, 943
 - apomorphine, 859
 - avoidance, 943
 - behavioral arousal, 667
 - chlordiazepoxide, 279
 - dopamine, 667, 859
 - dopamine receptor blockade, 67
 - 6-hydroxydopamine, neonatal, 279
 - intertrial response, 943
 - multiple schedule, 667
 - norepinephrine depletion, 279
 - operant responding, 667
 - pimozide, 67, 667
 - punishment-conflict, 279
 - reinforcement, 667
 - self-stimulation, 859
 - sensory-motor conditioning hypothesis, 67
 - shuttlebox, 943
 - stereotypy, 859
 - successive discrimination, 667
 - TRH, 943
- Fat
 - amphetamine, 303
 - anorexia, 303
 - caloric intake, 303, 949
 - carbohydrate, 303, 949
 - dietary self-selection, 303, 949
 - eating, 303, 949
 - β -endorphin, 949
 - fenfluramine, 303
 - morphine, 949
 - protein, 303, 949
- Fenfluramine, 303
 - amphetamine
 - anorexia
 - caloric intake
 - carbohydrate
 - dietary self-selection
 - eating
 - fat
 - protein
- Fentanyl, 249
 - D-Ala², D-Leu⁵-enkephalin
 - drug discrimination
 - ethylketocyclazocine
 - multiple opiate receptors
 - narcotics
- Ferret, 677
 - arecoline
 - central cholinergic mechanisms
 - nicotine
 - oxotremorine
 - predatory behavior
 - scopolamine
- Fetal ethanol, 585
 - corticosterone
 - hypothalamic-pituitary-adrenal system
 - prenatal ethanol
 - stress
- Finickiness, 293
 - dopamine theory of reward
 - hyperphagia
 - lesions, hypothalamic
 - licking behavior
 - pimozide
 - quinine
 - sweet reward
- Fixed interval
 - chained schedule, 271
 - drug interactions, 271
 - methadone, 271
 - morphine, 683
 - pentobarbital, 271
 - pigeons, 271, 683
 - schedule-induced escape, 683
- Fixed-ratio schedule
 - anticonvulsant drugs, 843
 - behavioral tolerance, 647
 - cerebral cortex, 647
 - concurrent schedule, 113
 - drinking, 113
 - drug concentration, 113
 - drug self-administration, oral, 113
 - neurotransmitter receptor binding, 647
 - pentobarbital reinforcement, 113
 - phencyclidine, 647
 - phenytoin, 843
 - pigeons, 843
 - rhesus monkeys, 113
 - tolerance, 843
 - water intake, 113
- FK 33-824, 989
 - hyperthermia
 - naloxone
 - opioid peptides
 - opioid receptors
 - thermoregulation
- Flight behavior, 397
 - bicuculline
 - dorsal periaqueductal gray
 - electrical stimulation
 - GABA mediation
 - picrotoxin
 - tranquilizers
- Food deprivation
 - aldosterone, 697
 - angiotensin II, 697
 - eating, 579
 - hypovolemia, 697
 - pentobarbital, 579

- plasma osmolality, 697
- rhesus monkeys, 579
- satiety, 579
- self-administration, 579
- sodium retention, 697
- Footshock
 - aggression, 63
 - ataxia, 63
 - brain region differences, 637
 - hallucinogens, 63
 - MHPG-SO₄, 637
 - noradrenaline turnover, 637
 - stress, 637
- Free-choice alcohol consumption, 501
 - alcohol preference
 - drinking
 - physical dependence
 - selective breeding
 - withdrawal
- Fusaric acid, 73
 - aggressive behavior
 - brain monoamines
 - dietary tyrosine
 - mice
 - motor activity
- GABA
 - aggressive behavior, 57
 - anxiety, 329, 689
 - aspartate, 509
 - barbiturates, 737
 - benzodiazepine receptors, 29
 - benzodiazepines, 29
 - chlordiazepoxide, 689
 - conditioned emotional response, 329
 - convulsant benzodiazepine, 689
 - cyclic GMP, 29
 - diazepam, 29
 - dopamine, 509
 - glutamate, 509
 - inbred mouse strains, 57
 - isolation, 57
 - morphine self-administration, 509
 - neurotransmitter metabolism, 329
 - neurotransmitter turnover rates, 509
 - norepinephrine, 509
 - opiate reinforcement systems, 509
 - ouabain, 29
 - phenobarbital, 737
 - Ro 5-3663, 689
 - rotation, 737
 - serotonin, 509
 - shock history, 329
 - substantia nigra, 737
 - stress, 329
- GABA mediation, 397
 - bicuculline
 - dorsal periaqueductal gray
 - electrical stimulation
 - flight behavior
 - picrotoxin
 - tranquilizers
- Gender differences, 757
 - chronic treatment
 - ethanol dependence
 - ethanol elimination rates
- Genotypic responses, 13
 - ethanol intoxication
 - ethanol sensitivity
 - inbred mice
- Gerbils, 377
 - attention
 - catecholamine interactions
- dopamine
 - habituation
 - locomotor activity
 - norepinephrine
 - sex differences
- d,l*-Glucine-1.5 phosphate, 851
 - abuse potential
 - rhesus monkeys
 - self-administration
- Glutamate, 509
 - aspartate
 - dopamine
 - GABA
 - morphine self-administration
 - neurotransmitter turnover rates
 - norepinephrine
 - opiate reinforcement systems
 - serotonin
- GM1 ganglioside, 611
 - analgesia
 - antiganglioside serum
 - cholera toxin
 - morphine receptors
- Gnawing, 407
 - dopamine
 - intrathecal injections
 - serotonin
 - tail-pinch
- Grooming
 - arousal, 929
 - homeostasis, 929
 - morphine withdrawal syndrome, 929
 - opiate antagonists, 653
 - plasma hormone levels, 653
 - RX 336-M, 929
 - social bonding, 653
 - talapoin monkeys, 653
 - wet-dog shakes, 929
- Habituation, 377
 - attention
 - catecholamine interactions
 - dopamine
 - gerbils
 - locomotor activity
 - norepinephrine
 - sex differences
- Hallucinogens
 - aggression, 63
 - ataxia, 63
 - cats, 51
 - discriminative stimulus properties, 553, 557
 - 2,5-DMA, 553
 - DOM, 557
 - DOM homologs, 557
 - DOM molecular modifications, 553
 - footshock, 63
 - LSD, 51
 - serotonin (5-HT), 51
 - l-tryptophan, 51
 - visual evoked responses, 51
- Haloperidol
 - antiapomorphine effect, 311
 - antihistamines, 979
 - anxiolytics, 979
 - benzodiazepine, 979
 - p-chloroamphetamine, 957
 - p-chlorophenylalanine, 957
 - chronic administration, 311
 - circadian rhythm, 311
 - clonidine, 785
 - clozapine, 785
 - corticosterone, 979

defecation, 979
 depression, animal model, 979
 development, 761
 diazepam, 957
 dopaminergic mechanisms, 957
 emotionality, 769
 hyperirritability, 769
 lesions, septal, 769
 methocarbamol, 785
 metoclopramide, 785
 neuroleptics, 979
 open field, 979
 operant conditioning, 761
 oxazepam, 979
 pemoline, 957
 pimozide, 957
 postnatal treatment, 761
 prazosin, 785
 recovery of function, 769
 self-injury, 957
 self-stimulation, 785
 septal rage, 769
 shuttlebox, 785
 spontaneous activity, 761
 tripeleennamine, 979

Hedonic deficit, 965
 antidepressants
 anxiolytics
 appetite
 chronic stress
 depression, animal model
 imipramine

High performance liquid chromatography, (HPLC), 131
 brain perfusion
 dihydroxyphenylacetic acid
 endogenous dopamine metabolites
 homovanillic acid
 5-hydroxyindoleacetic acid

High pressure liquid chromatography (HPLC), 641
 biogenic amine metabolites
 biogenic monoamine turnover
 dopamine
 norepinephrine
 one compartment electrochemical detector cell
 serotonin

Hippocampus
 cerebral asymmetry, 915
 copper, 915
 diazepam, 17
 hypothalamus, 17
 lateralization, 915
 self-stimulation, 17
 spatial behavior, 915
 zinc, 915

Histamine levels, 591
 diphenhydramine
 histidine decarboxylase
 plasma corticosterone
 stress

Histidine decarboxylase, 591
 diphenhydramine
 histamine levels
 plasma corticosterone
 stress

Histidyl-proline diketopiperazine, 225
 appetite
 bicuculline
 bombesin
 calcitonin
 cholecystokinin octapeptide
 eating
 naloxone
 norepinephrine-induced feeding
 thyrotropin releasing hormone

5-HT receptor, 7
 contralateral turning behavior
 dopaminergic system
 dorsal raphe lesions
 6-hydroxydopamine
 medial forebrain bundle lesions
 5-methoxy-N,N-dimethyltryptamine

Homeostasis, 929
 arousal
 grooming
 morphine withdrawal syndrome
 RX 336-M
 wet-dog shakes

Homovanillic acid
 brain perfusion, 131
 dihydroxyphenylacetic acid, 131
 dopamine metabolism, 229
 endogenous dopamine metabolites, 131
 HPLC, 131
 5-hydroxyindoleacetic acid, 131
 MIF-1, 229
 norepinephrine metabolism, 229
 serotonin metabolism, 229
 striatum, 229
 tyrosine hydroxylase, 229

Hormone
 aldosterone, 697
 5 α -androstane-3 β ,17 β -diol, 837
 cortisol, 653
 5 α -dihydrotestosterone, 211, 837
 estradiol, 837
 17 β -estradiol, 285
 estradiol benzoate, 93
 estriol, 93
 estrogen, 211, 875
 estrone, 93
 insulin, 1001
 luteinizing hormone, 653
 progesterone, 875
 prolactin, 653
 testosterone, 653, 933
 testosterone propionate, 41, 565

Human peripheral lymphocytes, 185
 abrin
 DNA synthesis
 protein synthesis
 virus transformed lymphocytes

6-Hydroxydopamine, 7
 dopaminergic system
 5-HT receptor
 ipsilateral turning behavior
 medial forebrain bundle lesions
 5-methoxy-N,N-dimethyltryptamine

6-Hydroxydopamine, neonatal, 279
 chlordiazepoxide
 extinction
 norepinephrine depletion
 punishment-conflict

5-Hydroxyindoleacetic acid
 alcohol preference, rats, 145
 brain perfusion, 131
 dihydroxyphenylacetic acid, 131
 dopamine, 145
 endogenous dopamine metabolites, 131
 homovanillic acid, 131
 HPLC, 131
 norepinephrine, 145
 regional brain monoamines, 145
 serotonin, 145

5-Hydroxytryptophan, 777
 p-chlorophenylalanine
 lordosis
 noradrenaline
 serotonin
 sexual behavior, female rat

- Hyperactivity
 - chronic opiate administration, 263
 - dopamine depletion, 151
 - environmental differences, 151
 - hypoactivity, 263
 - in utero* studies, rats, 263
 - morphine tolerance, 263
 - neonatal catecholamines, 151
 - norepinephrine depletion, 151
 - spontaneous activity, fetal rat, 263
 - withdrawal, 263
- Hyperactivity, haloperidol-induced, 1
 - amphetamine
 - animal models, hyperactivity
 - dopaminergic supersensitivity
 - lithium
 - methylphenidate
 - neonatal rats
- Hyperbaric pressure, 341
 - body temperature
 - brain-blood ethanol
 - ethanol antagonists
 - ethanol metabolism
 - ethanol narcosis
- Hyperirritability, 769
 - emotional
 - haloperidol
 - lesions, septal
 - recovery of function
 - septal rage
- Hyperosmolarity, 87
 - angiotensin II
 - drinking
 - hypovolemia
 - naloxone
 - opioids
- Hyperphagia, 293
 - dopamine theory of reward
 - finickiness
 - lesions, hypothalamic
 - licking behavior
 - pimozide
 - quinine
 - sweet reward
- Hypersensitivity, 119
 - dopamine receptors
 - locomotor activity
 - mesolimbic area
 - neuroleptics
 - opiates
 - 3H-spiroperidol binding
 - stereotypy
 - striatum
- Hyperthermia, 989
 - FK 33-824
 - naloxone
 - opioid peptides
 - opioid receptors
 - thermoregulation
- Hypoactivity
 - ataxia, 801
 - behavioral toxicology, 801
 - chronic opiate administration, 263
 - hyperactivity, 263
 - in utero* studies, rats, 263
 - lethality, 801
 - lithium isotopes, 801
 - morphine tolerance, 263
 - spontaneous activity, fetal rat, 263
 - withdrawal, 263
- Hypoglycemia, 1001
 - eating
 - insulin-induced feeding
 - naloxone
 - novel environment
- Hyponeophagia, 741
 - β -adrenoceptor antagonists
 - dopamine
 - 5-MeODMT
 - neophobia
 - serotonin
- Hypothalamic cytosol, 837
 - androgen receptors
 - 5 α -androstane-3 β ,17 β -diol
 - estrogen receptors
 - lordosis
 - mounting behavior
 - ovariectomy
 - sexual behavior, female rat
- Hypothalamic hyperphagia, 101
 - eating
 - knife cuts, hypothalamus
 - noradrenergic feeding
 - norepinephrine
 - obesity
- Hypothalamic-pituitary-adrenal system, 585
 - corticosterone
 - fetal ethanol
 - prenatal ethanol
 - stress
- Hypothalamic temperature, 23
 - body temperature
 - capsaicin
 - thermoregulation
- Hypothalamus
 - aggression, 41
 - androgens, 41
 - diazepam, 17
 - hippocampus, 17
 - self-stimulation, 17
- Hypothermia
 - alcohol, 321
 - ambient temperature, 903
 - blood glucose levels, 903
 - body temperature, 903
 - calcium-sodium ratio, 321
 - dopamine, 321
 - drug interactions, 473
 - ethanol, 321, 473, 903
 - metabolism, 361
 - morphine, 473
 - norepinephrine, 321
 - opiates, 473
 - pharmacogenetics, 473
 - poikilothermia, 321
 - pyridoxine, 361
 - selective breeding, 473
 - serotonin (5-HT), 321
 - temperature set-point, 321
 - thermoregulation, 321
 - tolerance, 903
 - vitamin B₆, 361
- Hypovolemia
 - aldosterone, 697
 - angiotensin II, 87, 697
 - drinking, 87
 - food deprivation, 697
 - hyperosmolarity, 87
 - naloxone, 87
 - opioids, 87
 - plasma osmolality, 697
 - sodium retention, 697
- Imipramine
 - antidepressants, 965, 969
 - anxiolytics, 965
 - appetite, 965
 - chronic stress, 965
 - defecation, 969

- depression, animal model, 965, 969
- hedonic deficit, 965
- open field, 969
- stress, 969
- Inbred mouse strains
 - aggressive behavior, 57
 - ethanol intoxication, 13
 - ethanol sensitivity, 13
 - GABA, 57
 - genotypic responses, 13
 - isolation, 57
 - locomotor activity, 561
 - naloxone, 561
 - naltrexone, 561
- Insulin-induced feeding, 1001
 - eating
 - hypoglycemia
 - naloxone
 - novel environment
- Integrated plasma sampling, 521
 - acute venous catheterization
 - blood sample collection
 - primates
- Intertrial response, 943
 - acquisition
 - avoidance
 - extinction
 - shuttlebox
 - TRH
- Intrathecal injections, 407
 - dopamine
 - gnawing
 - serotonin
 - tail-pinch
- In utero* studies, rats, 263
 - chronic opiate administration
 - hyperactivity
 - hypoactivity
 - morphine tolerance
 - spontaneous activity, fetal rat
 - withdrawal
- Iprindole, 973
 - antidepressants
 - buprion
 - depression, animal model
 - mianserine
 - plasma corticosterone
 - stress
- Ipsilateral turning behavior, 7
 - dopaminergic system
 - 5-HT receptor
 - 6-hydroxydopamine
 - medial forebrain bundle lesions
 - 5-methoxy-N,N-dimethyltryptamine
- Isolation
 - aggressive behavior, 57
 - catecholamines, 417
 - GABA, 57
 - inbred mouse strains, 57
 - play, 417
 - psychomotor stimulants, 417
 - social behavior, 417
- Isolation rearing, 841
 - behavioral efficacy
 - opiates
 - receptor binding
- Isoproterenol, 627
 - brown adipose tissue
 - obesity
 - thermogenesis
 - Zucker rats
- Kindling, 1009
 - afterdischarge thresholds
 - amygdala
 - phencyclidine
 - seizures
- Kindling, amygdaloid, 751
 - opiates
 - seizures
- Kindling, olfactory bulb, 855
 - afterdischarge threshold
 - cocaine
- Kinetic isotope effect, 811
 - behavior disruption
 - proteo-N,N-dimethyltryptamine
 - tetradetero-N,N-dimethyltryptamine
- Knife cuts, hypothalamus, 101
 - eating
 - hypothalamic hyperphagia
 - noradrenergic feeding
 - norepinephrine
 - obesity
- LSD, 51
 - cats
 - hallucinogens
 - serotonin (5-HT)
 - l-tryptophan
 - visual evoked responses
- Lateralization, 915
 - cerebral asymmetry
 - copper
 - hippocampus
 - spatial behavior
 - zinc
- Lead acetate, 631
 - amphetamine
 - brain weight
 - cocaine
 - mouse genotype
 - seizures
- Learned helplessness, 449
 - antidepressants
 - anxiolytics
 - depressants
 - depression
 - electroconvulsive shock
 - neuroleptics
 - stimulants
- Lesions, 7
 - contralateral turning
 - dorsal raphe
 - 6-hydroxydopamine
 - medial forebrain bundle
 - 5-methoxy-N,N-dimethyltryptamine
- Lesions, electrolytic
 - asymmetry, 455
 - catecholamines, 455
 - 5 α -dihydrotestosterone, 211
 - estrogen, 211
 - lesions, nigrostriatal, 455
 - lesions, 6-OHDA, 211, 455
 - lesions, septal nuclei, 211
 - lesions, substantia nigra, 455
 - lordosis, 211
 - mesolimbic dopamine pathway, 211
 - ovariectomy, 211
 - sensorimotor dysfunction, 455
 - sensory extinction, 455
 - sexual behavior, female rat, 211
- Lesions, hypothalamic 293
 - dopamine theory of reward
 - finickiness
 - hyperphagia
 - licking behavior
 - pimozide
 - quinine
- Kindling, 1009
 - afterdischarge thresholds

- sweet reward
- Lesions, nigrostriatal, 455
 - asymmetry
 - catecholamines
 - lesions, electrolytic
 - lesions, 6-OHDA
 - lesions, substantia nigra
 - sensorimotor dysfunction
 - sensory extinction
- Lesions, 6-OHDA
 - aggression, 547
 - asymmetry, 455
 - catecholamines, 455
 - 5 α -dihydrotestosterone, 211
 - dopaminergic system, 547
 - estrogen, 211
 - lesions, electrolytic, 211, 455
 - lesions, nigrostriatal, 455
 - lesions, septal nuclei, 211
 - lesions, substantia nigra, 455
 - lordosis, 211
 - mesocorticolimbic system, 547
 - mesolimbic dopamine pathway, 211
 - muricide, 547
 - ovariectomy, 211
 - sensorimotor dysfunction, 455
 - sensory extinction, 455
 - sexual behavior, female rat, 211
 - ventral mesencephalic tegmental area (nucleus A10), 547
- Lesions, septal
 - 5 α -dihydrotestosterone, 211
 - emotionality, 769
 - estrogen, 211
 - haloperidol, 769
 - hyperirritability, 769
 - lesions, electrolytic, 211
 - lesions, 6-OHDA, 211
 - lordosis, 211
 - mesolimbic dopamine pathway, 211
 - ovariectomy, 211
 - recovery of function, 769
 - septal rage, 769
 - sexual behavior, female rat, 211
- Lesions, substantia nigra, 455
 - asymmetry
 - catecholamines
 - lesions, electrolytic
 - lesions, nigrostriatal
 - lesions, 6-OHDA
 - sensorimotor dysfunction
 - sensory extinction
- Lethality, 801
 - ataxia
 - behavioral toxicology
 - hypoactivity
 - lithium isotopes
- Lever pressing, 423
 - atropine methylnitrate
 - atropine sulfate
 - motor control
 - rhesus monkey
- Licking behavior, 293
 - dopamine theory of reward
 - finickiness
 - hyperphagia
 - lesions, hypothalamic
 - pimozide
 - quinine
 - sweet reward
- Ligand binding, 245
 - benzodiazepine receptors
 - diazepam
 - multicomponent receptor
 - photoaffinity labeling
 - propyl- β -carboline-3-carboxylate
- sparing from inactivation
- Lithium, 1
 - amphetamine
 - animal models, hyperactivity
 - dopaminergic supersensitivity
 - hyperactivity, haloperidol-induced
 - methylphenidate
 - neonatal rats
- Lithium isotopes, 801
 - ataxia
 - behavioral toxicology
 - hypoactivity
 - lethality
- Lizards, 1017
 - MIF-1
 - sex differences
 - tonic immobility
- Locomotor activity
 - aggression, 569
 - attention, 377
 - catecholamine interactions, 377
 - dopamine, 377
 - dopamine receptors, 377
 - gerbils, 377
 - habituation, 377
 - hypersensitivity, 119
 - inbred strains, mice, 561
 - mesolimbic area, 119
 - methadone, 569
 - methysergide, 203
 - naloxone, 561
 - naltrexone, 561
 - neonates, mice, 203
 - neuroleptics, 119
 - norepinephrine, 377
 - opiates, 119
 - serotonergic development, 203
 - sex differences, 377
 - social behavior, 569
 - ³H-spiroperidol binding, 119
 - stereotypy, 119
 - striatum, 119
 - thyroxine, 203
- Lordosis
 - androgen receptors, 837
 - 5 α -androstane-3 β ,17 β -diol, 837
 - p-chlorophenylalanine, 777
 - 5 α -dihydrotestosterone, 211
 - estrogen, 211
 - estrogen receptors
 - 5-hydroxytryptophan, 777
 - hypothalamic cytosol, 837
 - lesions, electrolytic, 211
 - lesions, 6-OHDA, 211
 - lesions, septal nuclei, 211
 - mesolimbic dopamine pathway, 211
 - mounting behavior, 837
 - noradrenaline, 777
 - ovariectomy, 211, 837
 - serotonin, 777
 - sexual behavior, female rat, 211, 777, 837
- Macaque monkey, female, 995
 - amine-aldehyde metabolites
 - drug interaction
 - ethanol self-selection
 - route of delivery
 - tetrahydropapaveroline, ICV infusion
- Marijuana cannabinoids, 573
 - cobalt epilepsy
 - REM sleep
 - seizures, epileptic
 - tetrahydrocannabinols

Matching-to-sample, 713
 cocaine
 conditional discrimination
 memory
 pigeons
 tolerance

Maturation, 217
 age differences
 amphetamine
 avoidance
 catecholamines
 motor activity

Maudsley rats, 707
 alcohol
 drinking
 drug interaction
 morphine
 selective breeding
 strain differences

Medial forebrain bundle lesions, 7
 dopaminergic system
 5-HT receptor
 6-hydroxydopamine
 ipsilateral turning behavior
 5-methoxy-N,N-dimethyltryptamine

Memory, 713
 cocaine
 conditional discrimination
 matching-to-sample
 pigeons
 tolerance

Memory retrieval, 463
 amnesia
 anisomycin
 passive avoidance
 vasopressin

Memory, spatial, 919
 anticholinergic drugs
 memory, working
 scopolamine

Memory, working, 919
 anticholinergic drugs
 memory, spatial
 scopolamine

Meperidine, 1005
 analgesia
 diazepam
 drug interaction
 normeperidine
 proconvulsive effects

Mesocorticolimbic system, 547
 aggression
 dopaminergic system
 lesions, 6-OHDA
 muricide
 ventral mesencephalic tegmental area (nucleus A10)

Mesolimbic area, 119
 dopamine receptors
 hypersensitivity
 locomotor activity
 neuroleptics
 opiates
³H-spiroperidol binding
 stereotypy
 striatum

Mesolimbic dopamine pathway, 211
 5 α -dihydrotestosterone
 estrogen
 lesions, electrolytic
 lesions, 6-OHDA
 lesions, septal nuclei
 lordosis
 ovariectomy
 sexual behavior, female rat

Metabolism, 361
 hypothermia
 pyridoxine
 vitamin B₆

Methadone
 aggression, 569
 chained schedule, 271
 drug interactions, 271
 fixed interval, 271
 locomotor activity, 569
 pentobarbital, 271
 pigeons, 271
 social behavior, 569

Methaqualone, 925
 pituitary-adrenal system
 plasma corticosterone
 sedative-hypnotics

Methocarbamol, 785
 clonidine
 clozapine
 halperidol
 metoclopramide
 prazosin
 self-stimulation
 shuttlebox

Method
 acute venous catheterization, 521
 continuous infusion, 725
 HPLC, 131, 641
 photoaffinity labeling, 245

5-Methoxy-N,N-dimethyltryptamine (5-MeODMT)
 β -adrenoceptor antagonists, 741
 contralateral turning behavior, 7
 dopamine, 741
 dopaminergic system, 7
 dorsal raphe lesion, 7
 5-HT receptor, 7
 6-hydroxydopamine, 7
 hyponeophagia, 741
 ipsilateral turning behavior, 7
 medial forebrain bundle lesions, 7
 neophobia, 741
 serotonin, 741

3-Methoxy-4-hydroxyphenylethylene glycol sulfate (MHPG-SO₄)
 brain region differences, 315, 637
 footshock, 637
 noradrenaline turnover, 315, 637
 plasma corticosterone, 315
 stress, 637
 stress, immobilization, 315
 time-related differences, 315

Methylphenidate, 1
 amphetamine
 animal models, hyperactivity
 dopaminergic supersensitivity
 hyperactivity, haloperidol-induced
 lithium
 neonatal rats

Methysergide, 203
 locomotor activity
 neonates, mice
 serotonergic development
 thyroxine

Metoclopramide, 785
 clonidine
 clozapine
 haloperidol
 methocarbamol
 prazosin
 self-stimulation
 shuttlebox

Mianserine, 973
 antidepressants
 buprion
 depression, animal model

- iprindole
- plasma corticosterone
- stress
- Mice, 73
 - aggressive behavior
 - brain monoamines
 - dietary tyrosine
 - fusaric acid
 - motor activity
- MIF-1
 - dopamine metabolism, 229
 - homovanillic acid, 229
 - lizards, 1017
 - norepinephrine metabolism, 229
 - serotonin metabolism, 229
 - sex differences, 1017
 - striatum, 229
 - tonic immobility, 1017
 - tyrosine hydroxylase, 229
- Milk-induced behavior, 481
 - mouthng
 - rat pups
 - serotonergic agents
- Mitochondrial function, 207
 - cardiac mass
 - ethanol
 - swimming
- Monoamine oxidase, 429
 - clorgyline
 - drug administration, "lifetime"
 - drug administration, subacute
 - REM sleep
 - sleep stages
- Monoamines, 441
 - catecholamines
 - convulsions, tonic
 - development
 - electroshock
 - serotonin
- Morphine
 - alcohol, 707
 - analgesia, 869
 - caloric intake patterns, 949
 - carbohydrate, 949
 - dietary self-selection, 949
 - drinking, 707
 - drug interaction, 473, 707
 - eating, 949
 - β -endorphin, 949
 - ethanol sensitivity, 473
 - fat, 949
 - fixed interval, 683
 - hypothermia, 473
 - Maudsley rats, 707
 - nociceptive stimuli, 869
 - opiates, 473
 - pharmacogenetics, 473
 - pigeons, 683
 - protein, 949
 - schedule-induced escape, 683
 - selective breeding, 473, 707
 - startle reflex, 869
 - strain differences, 707
- Morphine-dependent rats, 167
 - butorphanol
 - drug self-administration
 - nalbuphine
 - pentazocine
 - physical dependence
- Morphine-induced behavior suppression, 621
 - autoshaped behavior
 - opiate receptor alkylators
- Morphine receptors, 611
 - analgesia
 - antiganglioside serum
 - choleragenoid
 - GM1 ganglioside
- Morphine self-administration, 509
 - aspartate
 - dopamine
 - GABA
 - glutamate
 - neurotransmitter turnover rates
 - norepinephrine
 - opiate reinforcement systems
 - serotonin
- Morphine tolerance, 263
 - chronic opiate administration
 - hyperactivity
 - hypoactivity
 - in utero* studies, rats
 - spontaneous activity, fetal rat
 - withdrawal
- Morphine withdrawal, 35
 - alcohol-opiate commonalities
 - ethanol sensitivity
 - opiate dependence
- Morphine withdrawal syndrome, 929
 - arousal
 - grooming
 - homeostasis
 - RX 336-M
 - wet-dog shakes
- Motor activity
 - age differences, 217
 - aggressive behavior, 73
 - amphetamine, 217
 - avoidance, 217
 - brain monoamines, 73
 - catecholamines, 217
 - dietary tyrosine, 73
 - fusaric acid, 73
 - maturation, 217
 - mice, 73
- Motor control, 423
 - atropine methylnitrate
 - atropine sulfate
 - lever pressing
 - rhesus monkey
- Motor responses, 731
 - alpha adrenergic antagonists
 - alpha-2 receptors
 - autonomic responses
 - extrapyramidal effects
 - reserpine rigidity
- Mounting behavior, 837
 - androgen receptors
 - 5 α -androstane-3 β ,17 β -diol
 - estrogen receptors
 - hypothalamic cytosol
 - lordosis
 - ovariectomy
 - sexual behavior, female rat
- Mouse genotype, 631
 - amphetamine
 - brain weight
 - cocaine
 - lead acetate
 - seizures
- Mouthng, 481
 - milk-induced behavior
 - rat pups
 - serotonergic agents
- Multicomponent receptor, 245
 - benzodiazepine receptors
 - diazepam
 - ligand binding
 - photoaffinity labeling
 - propyl- β -carboline-3-carboxylate
 - sparing from inactivation

Multiple opiate receptors, 249
 drug discrimination
 D-Ala², D-Leu³-enkephalin
 ethylketocyclazocine
 fentanyl
 narcotics
 Multiple schedule
 behavioral arousal, 667
 dopamine, 667
 drug interaction, 159
 extinction, 667
 operant responding, 159, 667
 patas monkeys, 159
 pentobarbital, 159
 phencyclidine, 159
 pimozide, 667
 reinforcement, 667
 response chains, 159
 successive discrimination, 667
 supra-additive effects, 159
 Muricide, 547
 aggression
 dopaminergic system
 lesions, 6-OHDA
 mesocorticolimbic system
 ventral mesencephalic tegmental area (nucleus A10)

Nalbuphine, 167
 butorphanol
 drug self-administration
 morphine-dependent rats
 pentazocine
 physical dependence

Naloxone
 alcohol, 827
 amine-aldehyde condensation product, 827
 amphetamine, 433
 angiotensin II, 87
 appetite, 225
 bicuculline, 225
 bombesin, 225
 calcitonin, 225
 central reward mechanisms, 1013
 cholecystokinin octapeptide, 225
 drinking, 87, 173, 827, 1013
 dorsal tegmentum, 433
 eating, 225, 1001, 1013
 endorphins, 173, 599
 FK 33-824, 989
 histidyl-proline diketopiperazine, 225
 hyperosmolarity, 87
 hyperthermia, 989
 hypoglycemia, 1001
 hypovolemia, 87
 inbred strains, mice, 561
 insulin-induced feeding, 1001
 locomotor activity, 561
 naloxone, 989
 naltrexone, 561, 1013
 norepinephrine-induced feeding, 225
 novel environment, 1001
 operant behavior, 1013
 opiate antagonists, 1013
 opiate receptors, 827
 opioid peptides, 989
 opioid receptors, 989
 opioids, 87
 prefrontal cortex, 433
 respiration, 599
 reward, 433
 salsolinol, 827
 self-stimulation, 433
 stress, 599
 tetrahydropapaveroline, 827
 thermoregulation, 989
 thyrotropin releasing hormone, 225

Naltrexone
 appetite, 909
 central reward mechanisms, 1013
 drinking, 909, 1013
 eating, 909, 1013
 inbred strains, mice, 561
 locomotor activity, 561
 naloxone, 561, 1013
 operant behavior, 1013
 opiate antagonists, 1013
 renal electrolyte excretion, 909
 renal water excretion, 909
 water exchange, 909

Narcotics
 abstinence syndrome, 725
 continuous infusion, 725
 dependence liability, 725
 drug discrimination, 249
 D-Ala², D-Leu³-enkephalin, 249
 ethylketocyclazocine, 249
 fentanyl, 249
 multiple opiate receptors, 249
 opiates, 725

Neonatal catecholamines, 151
 dopamine depletion
 environmental differences
 hyperactivity
 norepinephrine depletion

Neonatal treatment, 241
 analgesia
 capsaicin
 nociceptive stimuli

Neonatal rats, 1
 amphetamine
 animal models, hyperactivity
 dopaminergic supersensitivity
 hyperactivity, haloperidol-induced
 lithium
 methylphenidate

Neonates, mice, 203
 locomotor activity
 methysergide
 serotonergic development
 thyroxine

Neophobia, 741
 β -adrenoceptor antagonists
 dopamine
 hyponeophagia
 5-MeODMT
 serotonin

Neurohypophyseal hormone analogs, 819
 behavioral effects
 oxytocin
 structure-activity
 vasopressin

Neuroleptics
 acetylcholine, 533
 activity, 411
 antidepressants, 449
 antihistamines, 979
 anxiolytics, 449, 979
 avoidance, 541
 benzodiazepine, 979
 catalepsy, 533
 cold water swims, 411
 corticosterone, 979
 defecation, 979
 depressants, 449
 depression, 449
 depression, animal model, 979
 dopamine, 533
 dopamine receptors, 119
 drug interaction, 411

- electroconvulsive shock, 449
- haloperidol, 979
- hypersensitivity, 119
- learned helplessness, 449
- locomotor activity, 119
- mesolimbic area, 119
- opiate analgesia, 411
- opiates, 119
- open field, 979
- oxazepam, 979
- pain, 411
- postnatal development, 533
- reversal learning, 541
- spatial preference, 541
- ³H-spiroperidol binding, 119
- stereotypy, 119
- stimulants, 449
- striatectomy, 541
- striatum, 119
- tripelennamine, 979
- Y-maze performance, 541
- Neurotransmitter metabolism, 329
 - anxiety
 - conditioned emotional response
 - GABA
 - shock history
 - stress
- Neurotransmitter receptor binding, 647
 - behavioral tolerance
 - cerebral cortex
 - fixed-ratio responding
 - phencyclidine
- Neurotransmitter turnover rates, 509
 - aspartate
 - dopamine
 - GABA
 - glutamate
 - morphine self-administration
 - norepinephrine
 - opiate reinforcement systems
 - serotonin
- Nicotine, 677
 - arecoline
 - central cholinergic mechanisms
 - ferret
 - oxotremorine
 - predatory behavior
 - scopolamine
- Nitromifene citrate (CI-628), 93
 - eating
 - estrogen and food intake
 - ventromedial hypothalamus
- Nociceptive stimuli
 - analgesia, 241, 869
 - capsaicin, 421
 - morphine, 869
 - neonatal treatment, 241
 - startle reflex, 869
- Noradrenaline
 - p-chlorophenylalanine, 777
 - DSP-4, 197
 - 5-hydroxytryptophan, 777
 - lordosis, 777
 - operant behavior, 197
 - positive reinforcement, 197
 - serotonin, 777
 - sexual behavior, female rat, 777
- Noradrenaline turnover
 - brain region differences, 315, 637
 - footshock, 637
 - MHPG-SO₄, 315, 637
 - plasma corticosterone, 315
 - stress, 637
 - stress, immobilization, 315
 - time-related differences, 315
- Noradrenergic feeding, 101
 - eating
 - hypothalamic hyperphagia
 - knife cuts, hypothalamus
 - norepinephrine
 - obesity
- Norepinephrine
 - alcohol, 319
 - alcohol preference, rats, 145
 - antinociception, 47
 - aspartate, 509
 - attention, 377
 - biogenic amine metabolites, 641
 - biogenic monoamine turnover, 641
 - calcium-sodium ratio, 319
 - catecholamine interactions, 377
 - dopamine, 47, 145, 319, 377, 509, 641
 - eating, 101
 - ethanol, 319
 - GABA, 509
 - gerbils, 377
 - glutamate, 509
 - HPLC, 641
 - habituation, 377
 - 5-hydroxyindoleacetic acid, 145
 - hypothalamic hyperphagia, 101
 - hypothermia, 319
 - knife cuts, hypothalamus, 101
 - locomotor activity, 377
 - morphine self-administration, 509
 - neurotransmitter turnover rates, 509
 - noradrenergic feeding, 101
 - obesity, 101
 - one compartment electrochemical detector cell, 641
 - opiate reinforcement systems, 509
 - poikilothermia, 319
 - regional brain monoamines, 145
 - serotonin, 47, 145, 319, 509, 641
 - sex differences, 377
 - stress, 47
 - tail-flick, 47
 - temperature, set-point, 319
 - thermoregulation, 319
- Norepinephrine depletion
 - chlordiazepoxide, 279
 - dopamine depletion, 151
 - environmental differences, 151
 - extinction, 279
 - 6-hydroxydopamine, neonatal, 279
 - hyperactivity, 151
 - neonatal catecholamines, 151
 - punishment-conflict, 279
- Norepinephrine-induced feeding, 225
 - appetite
 - bicuculline
 - bombesin
 - calcitonin
 - cholecystokinin octapeptide
 - eating
 - histidyl-proline diketopiperazine
 - naloxone
 - thyrotropin releasing hormone
- Norepinephrine metabolism, 229
 - dopamine metabolism
 - homovanillic acid
 - MIF-1
 - serotonin metabolism
 - striatum
 - tyrosine hydroxylase
- Normeperidine, 1005
 - analgesia
 - diazepam
 - drug interaction
 - meperidine
 - proconvulsive effects

- Novel environment, 1001
 - eating
 - hypoglycemia
 - insulin-induced feeding
 - naloxone
- Obesity
 - brown adipose tissue, 627
 - eating, 101
 - hypothalamic hyperphagia, 101
 - isoproterenol, 627
 - knife cuts, hypothalamus, 101
 - noradrenergic feeding, 101
 - norepinephrine, 101
 - thermogenesis, 627
 - Zucker rats, 627
- 5-OH-5-ethyl-5-phenyl-butiramide, 177
 - anticonvulsants
 - convulsions, drug-induced
 - convulsions, electroshock-induced
 - electrocortical afterdischarges
- One compartment electrochemical detector cell, 641
 - biogenic amine metabolites
 - biogenic monoamine turnover
 - dopamine
 - HPLC
 - norepinephrine
 - serotonin
- Ontogeny, 615
 - post-decapitation reflex
 - spinal cord monoamines
- Open field
 - antidepressants, 969
 - antihistamines, 979
 - anxiolytics, 979
 - benzodiazepine, 979
 - corticosterone, 979
 - defecation, 969, 979
 - depression, animal model, 969, 979
 - haloperidol, 979
 - imipramine, 969
 - neuroleptics, 979
 - oxazepam, 979
 - stress, 969
 - tripelennamine, 979
- Operant behavior
 - benactyzine, 605
 - central reward mechanisms, 1013
 - drinking, 1013
 - drug interaction, 159
 - DSP-4, 197
 - eating, 1013
 - multiple schedule, 159
 - naloxone, 1013
 - naltrexone, 1013
 - noradrenaline, 197
 - opiate antagonists, 1013
 - patas monkeys, 159
 - pentobarbital, 159
 - phencyclidine, 159
 - pigeon, 487
 - positive reinforcement, 197
 - primate equilibrium platform, 605
 - profadol, 487
 - response chains, 159
 - rhesus monkey, 605
 - supra-additive effects, 159
- Operant conditioning, 761
 - development
 - haloperidol
 - postnatal treatment
 - spontaneous activity
- Operant responding, 667
 - behavioral arousal
 - dopamine
 - extinction
 - multiple schedule
 - pimozide
 - reinforcement
 - successive discrimination
- Opiate analgesia, 411
 - activity
 - cold water swims
 - drug interaction
 - neuroleptics
 - pain
- Opiate antagonists
 - central reward mechanisms, 1013
 - drinking, 1013
 - grooming, 653
 - eating, 1013
 - naloxone, 1013
 - naltrexone, 1013
 - operant behavior, 1013
 - plasma hormone levels, 653
 - social bonding, 653
 - talapoin monkeys, 653
- Opiate dependence, 35
 - alcohol-opiate commonalities
 - ethanol sensitivity
 - morphine withdrawal
- Opiate receptors, 827
 - alcohol
 - amine-aldehyde condensation product
 - drinking
 - naloxone
 - salsolinol
 - tetrahydropapaveroline
- Opiate receptor alkylators, 621
 - autoshaped behavior
 - morphine-induced behavior suppression
- Opiate reinforcement systems, 509
 - aspartate
 - dopamine
 - GABA
 - glutamate
 - morphine self-administration
 - neurotransmitter turnover rates
 - norepinephrine
 - serotonin
- Opiates
 - abstinence syndrome, 725
 - analgesia, 81
 - appetite, 701
 - behavioral efficacy, 541
 - bombesin, 701
 - bromergocryptine, 701
 - cholecystokinin octapeptide, 701
 - continuous infusion, 725
 - dependence liability, 725
 - dopamine receptors, 119
 - dopaminergic system, 701
 - drug interactions, 473
 - dynorphin, 701
 - eating, 701
 - ethanol sensitivity, 473
 - hypersensitivity, 119
 - hypothermia, 473
 - isolation rearing, 541
 - kindling, amygdaloid, 751
 - mesolimbic area, 119
 - morphine, 473
 - narcotics, 725
 - neuroleptics, 119
 - pharmacogenetics, 473
 - receptor binding, 541
 - satiety, 701
 - seizures, 751
 - selective breeding, 473

- self-stimulation, 81
- ³H-spiroperidol binding, 119
- stereotypy, 119
- striatum, 119
- thyrotropin-releasing hormone, 701
- Opioid peptides
 - FK 33-824, 989
 - hyperthermia, 989
 - naloxone, 989
 - opioid receptors, 989
 - opioids, 983
 - route of delivery, 983
 - thermoregulation, 983, 989
- Opioid receptors, 989
 - FK 33-824
 - hyperthermia
 - naloxone
 - opioid peptides
 - thermoregulation
- Opioids
 - angiotensin II, 87
 - drinking, 87
 - hyperosmolarity, 87
 - hypovolemia, 87
 - naloxone, 87
 - opioid peptides, 983
 - route of delivery, 983
 - thermoregulatory behavior, 983
- ORG 2766, potency and duration, 387
 - ACTH₄₋₁₀
 - active avoidance
 - [D-Phe⁷]ACTH₄₋₁₀, potency and duration
 - passive avoidance
- Ouabain, 29
 - benzodiazepine receptors
 - benzodiazepines
 - cyclic GMP
 - diazepam
 - GABA
- Ovariectomy
 - amphetamine, 565
 - androgen receptors, 837
 - 5 α -androstane-3 β ,17 β -diol, 837
 - castration, 565
 - 5 α -dihydrotestosterone, 211
 - estrogen, 211
 - estrogen receptors, 837
 - hypothalamic cytosol, 837
 - lesions, electrolytic, 211
 - lesions, 6-OHDA, 211
 - lesions, septal nuclei, 211
 - lordosis, 211, 837
 - mesolimbic dopamine pathway, 211
 - mounting behavior, 837
 - sex differences, 565
 - sexual behavior, female rat, 211, 837
 - stereotyped behavior, 565
- Overdrinking, 155
 - chronic ethanol intake
 - drinking
 - schedule-induced polydipsia
- Oxazepam
 - antihistamines, 979
 - antileptazol, 529
 - anxiolytics, 529, 979
 - benzodiazepine, 979
 - benzodiazepine receptors, 529
 - camazepam, 529
 - clobazam, 529
 - corticosterone, 979
 - defecation, 979
 - depression, animal model, 979
 - diazepam binding, 529
 - haloperidol, 979
 - neuroleptics, 979
 - open field, 979
 - temazepam, 529
 - tripelennamine, 979
- Oxotremorine, 677
 - arecoline
 - central cholinergic mechanisms
 - ferret
 - nicotine
 - predatory behavior
 - scopolamine
- Oxytocin, 819
 - behavioral effects
 - neurohypophyseal hormone analogs
 - structure-activity
 - vasopressin
- Pain
 - activity, 411
 - adrenalectomy, 403
 - analgesia, 403
 - cold water swims, 411
 - dexamethasone, 403
 - drug interaction, 411
 - neuroleptics, 411
 - opiate analgesia, 411
 - stress, 403
- Passive avoidance
 - ACTH₄₋₁₀, 387
 - active avoidance, 387
 - amnesia, 463
 - anisomycin, 463
 - [D-Phe⁷]ACTH₄₋₁₀, potency and duration, 387
 - memory retrieval, 463
 - ORG 2766, potency and duration, 387
 - vasopressin, 463
- Patas monkeys, 159
 - drug interaction
 - multiple schedule
 - operant behavior
 - pentobarbital
 - phencyclidine
 - response chains
 - supra-additive effects
- Pavlovian conditioning, 661
 - cocaine
 - conditional drug states
 - cross-potentialiation
 - pentobarbital
 - tolerance
- Pemoline, 957
 - p-chloroamphetamine
 - p-chlorophenylalanine
 - diazepam
 - dopaminergic mechanisms
 - haloperidol
 - pimozide
 - self-injury
- Pentazocine, 167
 - butorphanol
 - drug self-administration
 - morphine-dependent rats
 - nalbuphine
 - physical dependence
- Pentobarbital
 - albinism, 815
 - chained schedule, 271
 - chlordiazepoxide, 795
 - CL218,872, 795
 - cocaine, 661
 - conditional drug states, 661
 - conflict, 795
 - cross-potentialiation, 661
 - diazepam, 795
 - drug interaction, 159, 271

- eating, 579
- fixed interval, 271
- food deprivation, 579
- methadone, 271
- multiple schedule, 159
- operant behavior, 159
- patas monkeys, 159
- Pavlovian conditioning, 661
- phencyclidine, 159
- pigeons, 271
- response chains, 159
- response duration, 815
- rhesus monkeys, 579
- satiety, 579
- self-administration, oral
- self-stimulation, 795
- sex differences, 815
- shuttlebox, 795
- supra-additive effects, 159
- tolerance, 661
- Pentobarbital reinforcement, 113
 - concurrent schedules
 - drinking
 - drug concentration
 - drug self-administration, oral
 - fixed ratio schedules
 - rhesus monkeys
 - water intake
- Peptide
 - ACTH₄₋₁₀, 387
 - [D-Phe⁷]ACTH₄₋₁₀, 387
 - D-Ala²-Met-enkephalinamide, 983
 - D-Ala²-D-Leu-enkephalin, 983
 - angiotensin II, 87, 697
 - bombesin, 225, 701
 - calcitonin, 225
 - CCK-8, 225
 - cholecystokinin octapeptide, 701
 - dynorphin, 701
 - β -endorphin, 949
 - FK 33-824, 989
 - MIF-I, 229, 1017
 - ORG 2766, 387
 - oxytocin, 819
 - somatostatin, 897
 - thyrotropin-releasing hormone (TRH), 225, 701, 943
 - vasopressin, 139, 463, 819
- Pharmacogenetics, 473
 - drug interactions
 - ethanol sensitivity
 - hypothermia
 - morphine
 - opiates
 - selective breeding
- Phencyclidine
 - acute drug pretreatment, 847
 - afterdischarge thresholds, 1009
 - amygdala, 1009
 - autoshaping, 937
 - behavioral tolerance, 647
 - cerebral cortex, 647
 - chronic drug pretreatment, 847
 - drug interaction, 159, 847
 - ethanol, 847
 - exploratory behavior, 937
 - fixed-ratio responding, 647
 - kindling, 1009
 - multiple schedule, 159
 - neurotransmitter receptor binding, 647
 - operant behavior, 159
 - patas monkeys, 159
 - pentobarbital, 159
 - response chains, 159
 - seizures, 1009
 - supra-additive effects, 159
- Phenobarbital, 737
 - barbiturates
 - GABA
 - rotation
 - substantia nigra
- Phenytoin, 843
 - anticonvulsant drugs
 - fixed-ratio schedule
 - pigeons
 - tolerance
- Photoaffinity labeling, 245
 - benzodiazepine receptors
 - diazepam
 - ligand binding
 - multicomponent receptor
 - propyl- β -carboline-3-carboxylate
 - sparing from inactivation
- Physical dependence
 - adrenal medulla, 719
 - alcohol preference, 501
 - butorphanol, 167
 - catecholamines, 719
 - drinking, 501
 - drug self-administration, 167
 - ethanol, 719
 - free-choice alcohol consumption, 501
 - morphine-dependent rats, 167
 - nalbuphine, 167
 - pentazocine, 167
 - selective breeding, 501
 - withdrawal syndrome, 501, 719
- Picrotoxin, 397
 - bicuculline
 - dorsal periaqueductal gray
 - electrical stimulation
 - flight behavior
 - GABA mediation
 - tranquilizers
- Pigeons
 - anticonvulsant drugs, 843
 - chained schedule, 271
 - cocaine, 713
 - conditional stimulation, 713
 - drug interactions, 271
 - fixed interval schedule, 271, 683, 843
 - matching-to-sample, 713
 - memory, 713
 - methadone, 271
 - morphine, 683
 - operant behavior, 487
 - pentobarbital, 271
 - phenytoin, 843
 - profadol, 487
 - schedule-induced escape, 683
 - tolerance, 713, 843
- Pimozide
 - behavioral arousal, 667
 - p-chloroamphetamine, 957
 - p-chlorophenylalanine, 957
 - diazepam, 957
 - dopamine, 667
 - dopamine receptor blockade, 67
 - dopamine theory of reward, 293
 - dopaminergic mechanisms, 957
 - extinction, 67, 667
 - finickiness, 293
 - haloperidol, 957
 - hyperphagia, 293
 - lesions, hypothalamic, 293
 - licking behavior, 293
 - multiple schedule, 667
 - operant responding, 667
 - pemoline, 957
 - quinine, 293
 - reinforcement, 667

- self-injury, 957
- sensory-motor conditioning hypothesis, 67
- successive discrimination, 667
- sweet reward, 293
- Pipradrol, 791
 - d*-amphetamine
 - bupropion
 - self-stimulation
- Pituitary-adrenal system, 925
 - methaqualone
 - plasma corticosterone
 - sedative-hypnotics
- Plasma corticosterone
 - antidepressants, 973
 - brain, regional differences, 315
 - buprion, 973
 - depression, animal model, 973
 - diphenhydramine, 591
 - histamine levels, 591
 - histidine decarboxylase, 591
 - iprindole, 973
 - methaqualone, 925
 - MHPG-SO₁, 315
 - mianserine, 973
 - noradrenaline turnover, 315
 - pituitary-adrenal system, 925
 - sedative-hypnotics, 925
 - stress, 591, 973
 - stress, immobilization, 315
 - time-related differences, 315
- Plasma hormone levels, 653
 - grooming
 - opiate antagonists
 - social bonding
 - talapoin monkeys
- Plasma osmolality, 697
 - aldosterone
 - angiotensin II
 - food deprivation
 - hypovolemia
 - sodium retention
- Play, 417
 - catecholamines
 - isolation
 - psychomotor stimulants
 - social behavior
- Poikilothermia, 321
 - alcohol
 - calcium-sodium ratio
 - dopamine
 - ethanol
 - hypothermia
 - norepinephrine
 - serotonin (5-HT)
 - temperature set-point
 - thermoregulation
- Positive reinforcement, 197
 - DSP-4
 - noradrenaline
 - operant behavior
- Post-decapitation reflex, 615
 - ontogeny
 - spinal cord monoamines
- Postnatal development, 533
 - acetylcholine
 - catalepsy
 - dopamine
 - neuroleptics
- Postnatal treatment, 761
 - development
 - haloperidol
 - operant conditioning
 - spontaneous activity
- Prazosin, 785
 - clonidine
 - clozapine
 - haloperidol
 - methocarbamol
 - metoclopramide
 - self-stimulation
 - shuttlebox
- Predatory behavior, 677
 - arecoline
 - central cholinergic mechanisms
 - ferret
 - nicotine
 - oxotremorine
 - scopolamine
- Prefrontal cortex, 433
 - amphetamine
 - dorsal tegmentum
 - naloxone
 - reward
 - self-stimulation
- Prenatal ethanol, 585
 - corticosterone
 - fetal ethanol
 - hypothalamic-pituitary-adrenal system
 - stress
- Prepubertal male rat, 933
 - body weight
 - eating
 - testosterone
- Primates, 521
 - acute venous catheterization
 - blood sample collection
 - integrated plasma sampling
- Primate equilibrium platform, 605
 - benactyzine
 - operant behavior
 - rhesus monkey
- Proconvulsive effects, 1005
 - analgesia
 - diazepam
 - drug interaction
 - mepredine
 - normepredine
- Profadol, 487
 - operant behavior
 - pigeon
- Progesterone, 875
 - amphetamine
 - apomorphine
 - estrogen
 - sexual behavior, female rat
 - stereotyped behavior
- Propyl- β -carboline-3-carboxylate, 245
 - benzodiazepine receptors
 - diazepam
 - ligand binding
 - multicomponent receptor
 - photoaffinity labeling
 - sparing from inactivation
- Protein
 - amphetamine, 303
 - anorexia, 303
 - caloric intake, 303
 - caloric intake patterns, 949
 - carbohydrate, 303, 949
 - dietary self-selection, 303, 949
 - eating, 303, 949
 - β -endorphin, 949
 - fat, 303, 949
 - fenfluramine, 303
 - morphine, 949
- Protein synthesis, 185
 - abrin
 - DNA synthesis
 - human peripheral lymphocytes
 - virus transformed lymphocytes

Proteo-N,N-dimethyltryptamine, 811
 behavior disruption
 kinetic isotope effect
 tetradeutero-N,N-dimethyltryptamine
 Psychomotor stimulants, 417
 catecholamines
 isolation
 play
 social behavior
 Punishment-conflict, 279
 chlordiazepoxide
 extinction
 6-hydroxydopamine, neonatal
 norepinephrine depletion
 Pyridoxine, 361
 hypothermia
 metabolism
 vitamin B₆

Quinine, 293
 dopamine theory of reward
 finickiness
 hyperphagia
 lesions, hypothalamic
 licking behavior
 pimozide
 sweet reward

Rat pups, 481
 milk-induced behavior
 mouthing
 serotonergic agents
 Rate-dependency, 745
 caffeine
 schedule-controlled responding
 time course
 Receptor binding, 841
 behavioral efficacy
 isolation rearing
 opiates
 Recovery of function, 769
 emotionality
 haloperidol
 hyperirritability
 lesions, septal
 septal rage
 Regional brain monoamines, 145
 alcohol preference, rats
 dopamine
 5-hydroxyindoleacetic acid
 norepinephrine
 serotonin
 Reinforcement
 anesthetics, local, 491
 behavioral arousal, 667
 concurrent schedules, 393
 dopamine, 667
 drinking, 393
 drug discrimination, 491
 ethanol, 393
 extinction, 667
 multiple schedule, 667
 operant responding, 667
 pimozide, 667
 relative responding, 393
 self-administration, 491
 species differences, 491
 successive discrimination, 667
 Relative responding, 393
 concurrent schedules
 drinking
 ethanol
 reinforcement

REM sleep
 clorgyline, 429
 cobalt epilepsy, 573
 drug administration, "lifetime", 429
 drug administration, subacute, 429
 marijuana cannabinoids, 573
 monoamine oxidase, 429
 seizures, epileptic, 573
 sleep stages, 429
 tetrahydrocannabinols, 573
 Renal electrolyte excretion, 909
 appetite
 drinking
 eating
 naltrexone
 renal water excretion
 water exchange
 Renal water excretion, 909
 appetite
 drinking
 eating
 naltrexone
 renal electrolyte excretion
 water exchange
 Repeated sampling, 693
 blood ethanol
 breath ethanol analyzer
 Reserpine rigidity, 731
 alpha adrenergic antagonists
 alpha-2 receptors
 autonomic responses
 extrapyramidal effects
 motor responses
 Respiration, 599
 endorphins
 naloxone
 stress
 Response chains, 159
 drug interaction
 multiple schedule
 operant behavior
 patas monkeys
 pentobarbital
 phencyclidine
 supra-additive effects
 Response duration, 815
 albinism
 pentobarbital
 sex differences
 Response latency, 805
 avoidance training
 cholinergic system
 developmental psychopharmacology
 scopolamine
 Reversal learning, 541
 avoidance
 neuroleptics
 spatial preference
 striatectomy
 Y-maze performance
 Reward
 amphetamine, 433
 dorsal tegmentum, 433
 drug self-administration, 181
 ethanol, 181
 naloxone, 433
 prefrontal cortex, 433
 self-stimulation, 433
 Rhesus monkeys
 abuse potential, 851
 atropine methylnitrate, 423
 atropine sulfate, 423
 benactyzine, 605
 concurrent schedules, 113
 drinking, 113

- drug concentration, 113
- drug self-administration, oral, 113
- eating, 579
- fixed ratio schedules, 113
- food deprivation, 579
- d,l*-glucine-1.5 phosphate, 851
- level pressing, 423
- motor control, 423
- operant behavior, 605
- pentobarbital, 579
- pentobarbital reinforcement, 113
- primate equilibrium platform, 605
- satiety, 579
- self-administration, 851
- self-administration, oral, 579
- water intake, 113
- Righting reflex, 467
 - active avoidance
 - anxiety
 - anxiolytics
 - barbital
 - barbiturates
 - brain drug levels
 - drug administration, chronic
 - tolerance
- Ro 5-3663, 689
 - anxiety
 - chlordiazepoxide
 - convulsant benzodiazepine
 - GABA
- Rotation, 737
 - barbiturates
 - GABA
 - phenobarbital
 - substantia nigra
- Rotational behavior, 437
 - dopamine receptors
 - stereotyped behavior
- Rotometer, 353
 - automatic recording
 - circling behavior
- Route of delivery
 - amine-aldehyde metabolites, 995
 - drug interaction, 995
 - ethanol self-selection, 995
 - macaque monkey, female, 995
 - opioid peptides, 983
 - opioids, 983
 - tetrahydropapaveroline, ICV infusion, 995
 - thermoregulatory behavior, 983
- RX 336-M, 929
 - arousal
 - grooming
 - homeostasis
 - morphine withdrawal syndrome
 - wet-dog shakes

- Salsolinol, 827
 - alcohol
 - amine-aldehyde condensation product
 - drinking
 - naloxone
 - opiate receptors
 - tetrahydropapaveroline
- Satiety
 - appetite, 701
 - bombesin, 701
 - bromergocryptine, 701
 - cholecystokinin octapeptide, 701
 - dopaminergic system, 701
 - dynorphin, 701
 - eating, 579, 701, 897
 - food deprivation, 579
 - opiates, 701
 - pentobarbital, 579
 - rhesus monkeys, 579
 - self-administration, oral, 579
 - somatostatin, 897
 - thyrotropin-releasing hormone, 701
 - vagus nerve, 897
- Schedule-controlled responding, 745
 - caffeine
 - rate-dependency
 - time course
- Schedule-induced escape, 683
 - fixed interval
 - morphine
 - pigeons
- Schedule-induced polydipsia, 155
 - chronic ethanol intake
 - drinking
 - overdrinking
- Scopolamine
 - anticholinergic drugs, 919
 - arecoline, 677
 - avoidance training, 805
 - central cholinergic mechanisms, 677
 - cholinergic system, 805
 - developmental psychopharmacology, 805
 - ferret, 677
 - memory, spatial, 919
 - memory, working, 919
 - nicotine, 677
 - oxotremorine, 677
 - predatory behavior, 677
 - response latency, 805
- Sedative-hypnotics, 925
 - methaqualone
 - pituitary-adrenal system
 - plasma corticosterone
- Seizures
 - afterdischarge thresholds, 1009
 - amphetamine, 631
 - amygdala, 1009
 - brain weight, 631
 - cocaine, 631
 - kindling, 1009
 - kindling, amygdaloid, 751
 - lead acetate, 631
 - mouse genotype, 631
 - opiates, 751
 - phencyclidine, 1009
- Seizures, epileptic, 573
 - cobalt epilepsy
 - marijuana cannabinoids
 - REM sleep
 - tetrahydrocannabinols
- Selective breeding
 - alcohol, 707
 - alcohol preference, 125, 501
 - drinking, 501, 707
 - drug interaction, 473, 707
 - ethanol concentration and distribution, 125
 - ethanol sensitivity, 125, 473
 - free-choice alcohol consumption, 501
 - hypothermia, 473
 - Maudsley rats, 707
 - morphine, 473, 707
 - opiates, 473
 - pharmacogenetics, 473
 - physical dependence, 501
 - strain differences, 707
 - withdrawal, 501
- Self-administration
 - abuse potential, 851
 - anesthetics, local, 491
 - drug discrimination, 491
 - d,l*-glucine-1.5 phosphate, 851

- reinforcement, 491
- rhesus monkeys, 851
- species differences, 491
- Self-administration, oral, 579
 - eating
 - food deprivation
 - pentobarbital
 - rhesus monkeys
 - satiety
- Self-injury, 957
 - p-chloroamphetamine
 - p-chlorophenylalanine
 - diazepam
 - dopaminergic mechanisms
 - haloperidol
 - pemoline
 - pimozide
- Self-stimulation
 - amphetamine, 433
 - d*-amphetamine, 791
 - analgesia, 81
 - apomorphine, 859
 - bupropion, 791
 - chlordiazepoxide, 795
 - CL218,872, 795
 - clonidine, 785
 - clozapine, 785
 - conflict, 795
 - diazepam, 17, 795
 - dopamine, 859
 - dorsal tegmentum, 433
 - extinction, 859
 - haloperidol, 785
 - hippocampus, 17
 - hypothalamus, 17
 - methocarbamol, 785
 - metoclopramide, 785
 - naloxone, 433
 - opiates, 81
 - pentobarbital, 795
 - pipradol, 791
 - prazosin, 785
 - prefrontal cortex, 433
 - reward, 433
 - shuttlebox, 785, 791, 795
 - stereotypy, 859
- Sensorimotor dysfunction, 455
 - asymmetry
 - catecholamines
 - lesions, electrolytic
 - lesions, nigrostriatal
 - lesions, 6-OHDA
 - lesions, substantia nigra
 - sensory extinction
- Sensory extinction, 455
 - asymmetry
 - catecholamines
 - lesions, electrolytic
 - lesions, nigrostriatal
 - lesions, 6-OHDA
 - lesions, substantia nigra
 - sensorimotor dysfunction
- Sensory-motor conditioning hypothesis, 67
 - dopamine receptor blockade
 - extinction
 - pimozide
- Septal rage, 769
 - emotionality
 - haloperidol
 - hyperirritability
 - lesions, septal
 - recovery of function
- Serotonergic agents, 481
 - milk-induced behavior
 - mouthing
- rat pups
- Serotonergic development, 203
 - locomotor activity
 - methysergide
 - neonates, mice
 - thyroxine
- Serotonin (5-HT)
 - β -adrenoceptor antagonists, 741
 - alcohol, 321
 - alcohol preference, rats, 145
 - antinociception, 47
 - aspartate, 509
 - biogenic amine metabolites, 641
 - biogenic monoamine turnover, 641
 - calcium-sodium ratio, 321
 - cats, 51
 - catecholamines, 441
 - p-chlorophenylalanine, 777
 - convulsions, tonic, 441
 - development, 441
 - dopamine, 47, 145, 321, 407, 509, 641, 741
 - electroshock, 441
 - ethanol, 321
 - GABA, 509
 - glutamate, 509
 - gnawing, 407
 - hallucinogens, 51
 - HPLC, 641
 - 5-hydroxyindoleacetic acid, 145
 - 5-hydroxytryptophan, 777
 - hyponeophagia, 741
 - hypothermia, 321
 - intrathecal injections, 407
 - lordosis, 777
 - LSD, 51
 - 5-MeODMT, 741
 - monoamines, 441
 - morphine self-administration, 509
 - neophobia, 741
 - neurotransmitter turnover rates, 509
 - noradrenaline, 777
 - norepinephrine, 47, 145, 321, 509, 641
 - one compartment electrochemical detector cell, 641
 - opiate reinforcement systems, 509
 - poikilothermia, 321
 - regional brain monoamines, 145
 - sexual behavior, female rat, 777
 - stress, 47
 - tail-flick, 47
 - tail-pinch, 407
 - temperature set-point, 321
 - thermoregulation, 321
 - l-tryptophan, 51
 - visual evoked responses, 51
- Serotonin metabolism, 229
 - dopamine metabolism
 - homovanillic acid
 - MIF-1
 - norepinephrine metabolism
 - striatum
 - tyrosine hydroxylase
- Serotonin release, 881
 - active avoidance
 - central monoamines
 - p-chloroamphetamine
- Sex differences
 - albinism, 815
 - amphetamine, 565
 - attention, 377
 - castration, 565
 - catecholamine interactions, 377
 - dopamine, 377
 - gerbils, 377
 - habituation, 377
 - lizards, 1017

- locomotor activity, 377
- MIF-I, 1017
- norepinephrine, 377
- ovariectomy, 565
- pentobarbital, 815
- response duration, 815
- stereotyped behavior, 565
- tonic immobility, 1017
- Sexual behavior, female rat
 - amphetamine, 875
 - androgen receptors, 837
 - 5 α -androstane- β ,17 β -diol, 837
 - apomorphine, 875
 - p-chlorophenylalanine, 777
 - 5 α -dihydrotestosterone, 211
 - estrogen, 211, 875
 - estrogen receptors, 837
 - 5-hydroxytryptophan, 777
 - hypothalamic cytosol, 837
 - lesions, electrolytic, 211
 - lesions, 6-OHDA, 211
 - lesions, septal nuclei, 211
 - lordosis, 211, 777, 837
 - mesolimbic dopamine pathway, 211
 - mounting behavior, 837
 - noradrenaline, 777
 - ovariectomy, 211, 837
 - progesterone, 875
 - serotonin, 777
 - stereotyped behavior, 875
- Shock history, 329
 - anxiety
 - conditioned emotional response
 - GABA
 - neurotransmitter metabolism
 - stress
- Shuttlebox, 943
 - acquisition, 943
 - d*-amphetamine, 791
 - avoidance, 943
 - bupropion, 791
 - chlordiazepoxide, 795
 - CL218,872, 795
 - clonidine, 785
 - clozapine, 785
 - conflict, 795
 - diazepam, 795
 - extinction, 943
 - haloperidol, 785
 - intertrial response, 943
 - methocarbamol, 785
 - metoclopramide, 785
 - pentobarbital, 795
 - prazosin, 785
 - self-stimulation, 785, 791, 795
 - TRH, 943
- Sleep stages, 429
 - clorgyline
 - drug administration, "lifetime"
 - drug administration, subacute
 - monoamine oxidase
 - REM sleep
- Social behavior
 - aggression, 569
 - catecholamines, 417
 - isolation, 417
 - locomotor activity, 569
 - methadone, 569
 - play, 417
 - psychomotor stimulants, 417
- Social bonding, 653
 - grooming
 - opiate antagonists
 - plasma hormone levels
 - talapoin monkeys
- Sodium retention, 697
 - aldosterone
 - angiotensin II
 - food deprivation
 - hypovolemia
 - plasma osmolality
- Somatostatin, 897
 - eating
 - satiety
 - vagus nerve
- Sparing from inactivation, 245
 - benzodiazepine receptors
 - diazepam
 - ligand binding
 - multicomponent receptor
 - photoaffinity labeling
 - propyl- β -carboline-3-carboxylate
- Spatial behavior, 915
 - cerebral asymmetry
 - copper
 - hippocampus
 - lateralization
 - zinc
- Spatial preference, 541
 - avoidance
 - neuroleptics
 - reversal learning
 - striatectomy
 - Y-maze performance
- Species differences, 491
 - anesthetics, local
 - drug discrimination
 - reinforcement
 - self-administration
- Spinal cord monoamines, 615
 - ontogeny
 - post-decapitation reflex
- ³H-spiroperidol binding, 119
 - dopamine receptors
 - hypersensitivity
 - locomotor activity
 - mesolimbic area
 - neuroleptics
 - opiates
 - stereotypy
 - striatum
- Spontaneous activity
 - chronic opiate administration, 263
 - development, 761
 - haloperidol, 761
 - hyperactivity, 263
 - hypoactivity, 263
 - in utero* studies, rats, 263
 - morphine tolerance, 263
 - operant conditioning, 761
 - postnatal treatment, 761
 - withdrawal, 263
- Startle reflex, 869
 - analgesia
 - morphine
 - nociceptive stimuli
- Stereotyped behavior
 - amphetamine, 565, 875
 - apomorphine, 875
 - castration, 565
 - dopamine receptors, 437
 - estrogen, 875
 - ovariectomy, 565
 - progesterone, 875
 - rotational behavior, 437
 - sex differences, 565
 - sexual behavior, female rat, 875
- Stereotypy
 - apomorphine, 235, 859
 - dopamine, 859

- dopamine receptors, 119, 285
- dopaminergic agonists, 235
- estrogen, 285
- estrous cycle, female rat, 285
- extinction, 859
- hypersensitivity, 119
- locomotor activity, 119
- mesolimbic area, 119
- neuroleptics, 119
- opiates, 119
- self-stimulation, 859
- ³H-spiroperidol binding, 119
- striatal dopamine receptors, 235
- striatum, 119, 285
- Stimulants, 449
 - antidepressants
 - anxiolytics
 - depressants
 - depression
 - electroconvulsive shock
 - learned helplessness
 - neuroleptics
- Strain differences, 707
 - alcohol
 - drinking
 - drug interaction
 - Maudsley rats
 - morphine
 - selective breeding
- Stress
 - adrenalectomy, 403
 - alcohol dependence, 253
 - analgesia, 403
 - antinociception, 47
 - antidepressants, 969, 973
 - anxiety, 329
 - brain region differences, 637
 - buprion, 973
 - conditioned emotional response, 329
 - conditioned taste aversion, 253
 - corticosterone, 585
 - defecation, 969
 - depression, animal model, 969, 973
 - dexamethasone, 403
 - diphenhydramine, 591
 - dopamine, 47
 - endorphins, 599
 - fetal ethanol, 585
 - footshock, 637
 - GABA, 329
 - histamine levels, 591
 - histidine decarboxylase, 591
 - hypothalamic-pituitary-adrenal system, 585
 - imipramine, 969
 - iprindole, 973
 - MHPG-SO₄, 637
 - mianserine, 973
 - naloxone, 599
 - neurotransmitter metabolism, 329
 - noradrenaline turnover, 637
 - norepinephrine, 47
 - open field, 969
 - pain, 403
 - plasma corticosterone, 591, 973
 - prenatal ethanol, 585
 - respiration, 599
 - serotonin, 47
 - shock history, 329
 - tail-flick, 47
 - withdrawal, 253
- Stress, immobilization, 315
 - brain, regional differences
 - MHPG-SO₄
 - noradrenaline turnover
 - plasma corticosterone
 - time-related differences
- Striatal dopamine receptors, 235
 - apomorphine
 - dopaminergic agonists
 - stereotypy
- Striectomy, 541
 - avoidance
 - neuroleptics
 - reversal learning
 - spatial preference
 - Y-maze performance
- Striatum
 - dopamine metabolism, 229
 - dopamine receptors, 119, 285
 - estrogen, 285
 - estrous cycle, female rat, 285
 - homovanillic acid, 229
 - hypersensitivity, 119
 - locomotor activity, 119
 - mesolimbic area, 119
 - MIF-1, 229
 - neuroleptics, 119
 - norepinephrine metabolism, 229
 - opiates, 119
 - serotonin metabolism, 229
 - ³H-spiroperidol binding, 119
 - stereotypy, 119, 285
 - tyrosine hydroxylase, 229
- Structure-activity, 819
 - behavioral effects
 - neurohypophyseal hormone analogs
 - oxytocin
 - vasopressin
- Substantia nigra, 737
 - barbiturates
 - GABA
 - phenobarbital
 - rotation
- Successive discrimination, 667
 - behavioral arousal
 - dopamine
 - extinction
 - multiple schedule
 - operant responding
 - pimozide
 - reinforcement
- Supra-additive effects, 159
 - drug interaction
 - multiple schedule
 - operant behavior
 - patas monkeys
 - pentobarbital
 - phencyclidine
 - response chains
- Sweet reward, 293
 - dopamine theory of reward
 - finickiness
 - hyperphagia
 - lesions, hypothalamic
 - licking behavior
 - pimozide
 - quinine
- Swimming, 207
 - cardiac mass
 - ethanol
 - mitochondrial function
- Tail-flick, 47
 - antinociception
 - dopamine
 - norepinephrine
 - serotonin
 - stress

- Tail-pinch, 407
 - dopamine
 - gnawing
 - intrathecal injections
 - serotonin
- Talapoin monkeys, 653
 - grooming
 - opiate antagonists
 - plasma hormone levels
 - social bonding
- Temazepam, 529
 - antileptazol
 - anxiolytics
 - benzodiazepine receptors
 - camazepam
 - clobazam
 - diazepam binding
 - oxazepam
- Temperature set-point, 321
 - alcohol
 - calcium-sodium ratio
 - dopamine
 - ethanol
 - hypothermia
 - norepinephrine
 - poikilothermia
 - serotonin (5-HT)
 - thermoregulation
- Testosterone metabolism, 933
 - body weight
 - eating
 - prepubertal male rat
- Tetradeutero-N,N-dimethyltryptamine, 811
 - behavior disruption
 - kinetic isotope effect
 - proteo-N,N-dimethyltryptamine
- Tetrahydrocannabinols, 573
 - cobalt epilepsy
 - marijuana cannabinoids
 - REM sleep
 - seizures, epileptic
- Tetrahydropapveroline, 827
 - alcohol
 - amine-aldehyde condensation product
 - drinking
 - naloxone
 - opiate receptors
 - slasolinol
- Tetrahydropapaveroline, ICV infusion, 995
 - amine-aldehyde metabolites
 - drug interaction
 - ethanol self-selection
 - macaque monkey, female
 - route of delivery
- Thermogenesis, 627
 - brown adipose tissue
 - isoproterenol
 - obesity
 - Zucker rats
- Thermoregulation
 - alcohol, 321
 - body temperature, 23
 - calcium-sodium ratio, 321
 - capsaicin, 23
 - dopamine, 321
 - ethanol, 321
 - FK 33-824, 989
 - hyperthermia, 989
 - hypothalamic temperature, 23
 - hypothermia, 321
 - naloxone, 989
 - norepinephrine, 321
 - opiate peptides, 989
 - opiate receptors, 989
 - poikilothermia, 321
 - serotonin (5-HT), 321
 - temperature set-point, 321
- Thermoregulatory behavior, 983
 - opiate peptides
 - opioids
 - route of delivery
- Thyrotropin-releasing hormone (TRH)
 - acquisition, 943
 - appetite, 225, 701
 - avoidance, 943
 - bicuculline, 225
 - bombesin, 225, 701
 - bromergocryptine, 701
 - calcitonin, 225
 - cholecystokinin octapeptide, 225, 701
 - dopaminergic system, 701
 - dynorphin, 701
 - eating, 225, 701
 - extinction, 943
 - histidyl-proline diketopiperazine, 225
 - intertrial response, 943
 - naloxone, 225
 - norepinephrine-induced feeding, 225
 - opiates, 701
 - satiety, 701
 - shuttlebox, 943
- Thyroxine, 203
 - locomotor activity
 - methysergide
 - neonates, mice
 - serotonergic development
- Time course, 745
 - caffeine
 - rate-dependency
 - schedule-controlled responding
- Time-related differences, 315
 - brain, regional differences
 - MHPG-SO₄
 - noradrenaline turnover
 - plasma corticosterone
 - stress, immobilization
- Tolerance
 - active avoidance, 467
 - ambient temperature, 903
 - anticonvulsant drugs, 843
 - anxiety, 467
 - anxiolytics, 467
 - barbital, 467
 - barbiturates, 467
 - blood glucose levels, 903
 - body temperature, 903
 - brain drug levels, 467
 - cocaine, 661, 713
 - conditional discrimination, 713
 - conditional drug states, 661
 - cross-potential, 661
 - drug administration, chronic, 467
 - ethanol, 903
 - fixed-ratio schedule, 843
 - hypothermia, 903
 - matching-to-sample, 713
 - memory, 713
 - Pavlovian conditioning, 661
 - pentobarbital, 661
 - phenytoin, 843
 - pigeons, 713, 843
 - righting reflex, 467
- Tonic immobility, 1017
 - lizards
 - MIF-I
 - sex differences
- Tranquilizers, 397
 - bicuculline
 - dorsal periaqueductal gray
 - electrical stimulation

- flight behavior
- GABA mediation
- picrotoxin
- Triazolopyridazine CL218,872, 373
 - benzodiazepine receptors
 - brain, ovine
 - ³H-diazepam binding
- Tripelennamine, 979
 - antihistamines
 - anxiolytics
 - benzodiazepine
 - corticosterone
 - defecation
 - depression, animal model
 - haloperidol
 - neuroleptics
 - open field
 - oxazepam
- l-Tryptophan, 51
 - cats
 - hallucinogens
 - LSD
 - serotonin (5-HT)
 - visual evoked responses
- Tyrosine hydroxylase, 229
 - dopamine metabolism
 - homovanillic acid
 - MIF-1
 - norepinephrine metabolism
 - serotonin metabolism
 - striatum
- Vagus nerve, 897
 - eating
 - satiety
 - somatostatin
- Vasopressin
 - amnesia, 463
 - anisomycin, 463
 - behavioral effects, 819
 - brain, mouse, 139
 - cyclic AMP, 139
 - memory retrieval, 463
 - neurohypophyseal hormone analogs, 819
 - oxytocin, 819
 - passive avoidance, 463
 - structure-activity
- Ventral mesencephalic tegmental area (nucleus A10), 547
 - aggression
 - dopaminergic system
 - lesions, 6-OHDA
 - mesocorticolimbic system
 - muricide
- Ventromedial hypothalamus, 93
 - eating
 - estrogen and food intake
 - nitromifene citrate (CI-628)
- Virus transformed lymphocytes, 185
 - abrin
 - DNA synthesis
 - human peripheral lymphocytes
 - protein synthesis
- Visual evoked responses, 51
 - cats
 - hallucinogens
 - LSD
 - serotonin (5-HT)
- l-tryptophan
- Vitamin B₆, 361
 - hypothermia
 - metabolism
 - pyridoxine
- Water exchange, 909
 - appetite
 - drinking
 - eating
 - naltrexone
 - renal electrolyte excretion
 - renal water excretion
- Water intake, 113
 - concurrent schedules
 - drinking
 - drug concentration
 - drug self-administration, oral
 - fixed ratio schedules
 - pentobarbital reinforcement
 - rhesus monkeys
- Wet-dog shakes, 929
 - arousal
 - grooming
 - homeostasis
 - morphine withdrawal syndrome
 - RX 336-M
- Withdrawal
 - adrenal medulla, 719
 - alcohol dependence, 253
 - alcohol preference, 501
 - catecholamines, 719
 - chronic opiate administration, 263
 - conditioned taste aversion, 253
 - drinking, 501
 - ethanol, 719
 - free-choice alcohol consumption, 501
 - hyperactivity, 263
 - hypoactivity, 263
 - in utero* studies, rats, 263
 - morphine tolerance, 263
 - physical dependence, 501, 719
 - selective breeding, 501
 - spontaneous activity, fetal rat, 263
 - stress, 253
- Y-maze performance, 541
 - avoidance
 - neuroleptics
 - reversal learning
 - spatial preference
 - striatectomy
- Zinc, 915
 - cerebral asymmetry
 - copper
 - hippocampus
 - lateralization
 - spatial behavior
- Zucker rats, 627
 - brown adipose tissue
 - isoproterenol
 - obesity
 - thermogenesis

AUTHOR INDEX

- ALLAN, A. M., 35
ALLEN, D. L., 757
ADAMS, M. A., 719
AIGNER, T., 851
ALEXANDER, G. J., 801
ALKANA, R. L., 341
ANDERSON, R. J., 731
ARAVICH, P. F., 101
ARBUTHNOTT, G. W., 197
ARDIES, C. M., 207
ARUSHANIAN, E. B., 541
ATALAY, J., 841
- BAEZ, L. A., 533
BAKER, T. B., 253
BALDRIGHI, G., 969
BALSTER, R. L., 491
BARKER, S. A., 811
BARNES, C. D., 909
BARTNESS, T. J., 1001
BATURIN, V. A., 541
BAUER, R. H., 217
BAUM, M. J., 211
BEATON, J. M., 811
BEATTY, W. W., 417, 565, 919
BENINGER, R. J., 667
BENNETT, C. E., 185
BENNETT, C. T., 605
BERMAN, R. F., 751
BERMOND, B., 41
BERNARDINI, G. L., 989
BIALIK, R. J., 279
BIDZINSKI, A., 547
BIELKIEWICZ, B., 591
BLACKBURN, T. P., 7
BLASS, R. B., 235
BODNAR, R. J., 411
BOGGAN, W. O., 925
BOLAM, J. M., 815
BONNEY, R. C., 777
BLUM, K., 13
BRANCH, B. J., 585
BRANCH, M. N., 713
BRANDAO, M. L., 397
BREE, M. P., 521
BRICK, J., 473, 693
BRIGGS, A. H., 13
BRITT, M. D., 841
BROADHURST, P. L., 741
BROWN, C., 155
BROWN, J. W., 73
BROWN, R. E., 745
BURRIGHT, R. G., 631
BURT, D. K., 533
BUTERBAUGH, G. G., 441
BUXTON, D. A., 741
BUXTON, M., 151
- CACCIA, S., 529
CALCAGNETTI, D. J., 173
CAMPBELL, I. C., 429
CAMPBELL, K. A., 17
CAPPELL, H., 661
CAREY, R. J., 859
CARLSON, K. R., 119
CASHNER, F. M., 1017
CASTELLANO, C., 561
CAUDARELLA, M., 17
CAZA, P. A., 481
CHARLESON, S., 841
CHEAL, M. L., 377
CHEREK, D. R., 329
CLARK, W. G., 983, 989
CO, C., 509, 641
COHEN, R. M., 429
COLASANTI, B. K., 573
CONCANNON, J. T., 1
COTECCHIA, S., 529
COVENEY, J. R., 937
COWAN, A., 929
COX, B., 7
CRAIG, C. R., 573
CRAWFORD, D., 253
CRITCHER, E. C., 827
CROWNER, M. L., 533
- DALLEMAGNE, G., 761
DE AGUIAR, J. C., 397
DEARING, M. E., 713
DE-LA-CRUZ, F., 177
DELALLO, L., 13
DELATTE, S. W., 1017
DENOBLE, V. J., 113
DE RYCK, M., 285
DEWEY, W. L., 47
DE WIED, D., 387
DIB, B., 23
DIRINGER, M. N., 73
DODGE, A. M., 417, 565
DODGE, L. J., 417
DOERING, C. H., 837
DOLINSKY, Z., 631
DONOHOE, T. P., 93
DONOVICK, P. J., 631
DUCLAUX, R., 241
DUNCAN, P. M., 1009
- EGGLETON, C., 751
ELLIOTT, M. L., 63
ELSHOWIHY, R. M., 599
ELSTON, S. F. A., 13
ERICKSON, C. K., 207
- ERSKINE, M. S., 211
EVERARD, D. M., 777
- FABRE-NYS, C., 653
FALK, J. L., 155
FANELLI, R. J., 631
FARRAR, R. P., 207
FARRAR, S. B., 455
FARRER, D. N., 605
FEIGENBAUM, J. J., 235
FEKETE, M., 387
FELDON, J., 689
FELT, B. T., 139
FIBIGER, H. C., 197
FOLTIN, R. W., 347
FORSTER, M. J., 203
FRANKLIN, K. B. J., 433
FRAZIER, J. M., 915
FREEMAN, F. G., 1009
FREEMAN, M. E., 329, 509
FREEMAN, P. R., 569
FUJITA, N., 437
- GARATTINI, S., 529
GARDNER, E. L., 769
GERHARDT, S., 791, 795
GIESKE, T. H., 851
GILLIAM, P., 455
GILLIN, J. C., 429
GLADUE, B. A., 837
GLASSMAN, A. B., 185
GLENNON, R. A., 553, 557
GLUCKMAN, P. D., 373
GMEREK, D. E., 929
GODDING, P. R., 919
GOLDMAN, H., 139
GOLDSTEIN, F. J., 51
GRACE, M., 701
GRAEFF, F. G., 397
GRUNDMAN, M., 933
- HADFIELD, M. G., 359
HALL, N., 785
HANFORD, P. V., 467
HARRIS, P. S., 467
HARTMANN, G., 403
HARTWELL, S. W., 915
HARVEY, K. L., 521
HAUPTMANN, M., 547
HEAPY, C. G., 7
HENDRICKS, C., 855
HERZ, A., 249
HICKS, R. A., 361
HINSON, R. E., 661
HIRATA, A., 437

HIRSCH, J. D., 245
 HIRST, M., 719
 HOAKI, Y., 637
 HOLTZMAN, S. G., 263
 HOROWITZ, G. P., 35, 473
 HORWITZ, B. A., 627
 HOWE, S. J., 725
 HRUSKA, R. E., 285
 HUNGERFORD, S. M., 533

 IDA, Y., 315, 637
 IIMORI, K., 637
 INGS, R., 165
 ISOM, G. E., 599
 ISON, J. R., 869

 JARVIS, M. F., 1009
 JENSEN, M. A., 271
 JERUSSI, T. P., 353
 JOHANSON, C. E., 851
 JUDGE, M. E., 463

 KAMEYAMA, Y., 943
 KANAREK, R. B., 303
 KARPIAK, S. E., 611
 KATZ, R. J., 965, 969, 973, 979
 KELLAR, K. J., 647
 KEVERNE, E. B., 653
 KHAZAN, N., 167
 KIRBY, M. L., 263
 KLAWANS, H., 235
 KLINER, D. J., 579
 KNEIP, J., 225, 701
 KOHNO, Y., 315, 637
 KOKKA, N., 585
 KONDZIELSKI, M. H., 407
 KOSTOWSKI, W., 547
 KRAFFT, K., 843
 KRAMARCY, N. R., 73
 KRUK, M. R., 41

 LANE, J. D., 329, 509, 641
 LANG, I. M., 909
 LARSON, A. A., 407
 LEANDER, J. D., 487, 1005
 LEE, T. F., 7
 LEIBOWITZ, S. F., 101
 LE MAGNEN, J., 181
 LEVINE, A. S., 225, 897
 LEVINE, A. S., 701
 LEWIS, M. E., 29
 LI, T.-K., 125, 145, 501
 LIEBERMAN, K. W., 801
 LIEBMAN, J. M., 785, 791, 795
 LINDAMOOD III, C., 573
 LINDSETH, K. A., 361
 LITTLE, R. G. II, 757
 LIU, S. H., 585
 LIU, W.-F., 811
 LOBAUGH, N., 455
 LOF, N. E., 605
 LOGAN, N., 769
 LONDON, E. D., 441
 LUDMER, L. M., 285
 LUMENG, L., 125, 145, 501
 LUTHERER, L. O., 909

 McBRIDE, W. J., 125, 145, 501
 McCALEB, M. L., 995
 McCARTHY, P. S., 725, 1013
 McDEVITT, J. T., 737
 MALCOLM, R. D., 341
 MALSEED, R. T., 51
 MANDEL, P., 57
 MAREK, P., 403

 MARKS-KAUFMAN, R., 949
 MAROTTA, R. F., 769
 MASUR, J., 903
 MATTSSON, J. L., 605
 MAZURKIEWICZ-KWILECKI,
 I. M., 591
 MEELIS, W., 41
 MEIERL, G., 677
 MEISCH, R. A., 113, 579
 MEISENBERG, G., 819
 MELISKA, C. J., 745
 MELLER, R. E., 653
 MELLO, N. K., 521
 MENDELSON, W. B., 429
 MENNINI, T., 529
 MENNITI, F. S., 211
 MESSING, R. B., 621
 METCALF, G., 725
 MEYER, J. S., 925
 MEYERSON, B. J., 875
 MICHANEK, A., 875
 MICHELS, K., 631
 MILAM, K. M., 627
 MILGRAM, N. W., 17
 MINAMI, H., 311
 MISRA, A. L., 847
 MOERSCHBAECHER, J. M.,
 159, 647
 MOON, B., 235
 MOORE, K. E., 131
 MORLEY, J. E., 225, 701, 897
 MOS, J., 41
 MOTT, D. E. W., 359
 MUELLER, K., 957
 MURPHY, D. L., 429
 MURPHY, J. M., 145
 MURRAY, S. S., 225
 MYERS, R. D., 321, 827, 995
 MYSLOBODSKY, M., 689

 NAGASAKI, N., 315, 637
 NAGAYAMA, H., 311
 NAGY, Z. M., 203
 NAKAGAWA, R., 315, 637
 NICOTERA, N., 411
 NIELSEN, J. A., 131
 NISHIWAKI, K., 311
 NUGENT, E. A., 359
 NUNEZ, A. A., 933
 NYHAN, W. L., 957

 ÖGREN, S. O., 881
 OKAMOTO, M., 801
 OLIVEIRA SOUZA, M. L., 903
 OLSON, G. A., 1017
 OLSON, R. D., 1017
 ORTHEN-GAMBILL, N., 303

 PANKSEPP, J., 417
 PANOCKA, I., 403
 PAPPAS, B. A., 151, 279, 615
 PARROTT, R. F., 777
 PETERSEN, D. R., 757
 PETTY, F., 449
 PITMAN, K. T., 285
 PLONSKY, M., 569
 POHORECKY, L. A., 693
 POLING, A., 843
 PONDER, S. W., 989
 PONTANI, R. B., 847
 PORTOGHESE, P. S., 621
 POULOS, C. X., 661
 PRESHAW, R. L., 81
 PRESTON, K. L., 423

 PROWSE, J., 785, 791, 795
 PUCIŁOWSKI, O., 547
 PUGLISI-ALLEGRA, S., 57, 561
 PURVIS, P. L., 719
 PUSZTAY, W., 151, 279

 QUARTERMAIN, D., 463

 RASTOGI, R. B., 229
 REID, L. D., 173
 RICHTER, J. A., 467
 RIVERSO, S., 769
 ROBERTSON, A., 433
 ROEHRS, T. A., 393
 ROSECRANS, J. A., 553, 557
 ROSSI, G. V., 51
 ROWLAND, N., 87, 1001
 RUSH, J. R., 919
 RUSSEK, M., 177
 RUWE, W. D., 321, 995

 SACQUITNE, J. L., 449
 SAITO, K., 437
 SAMSON, H. H., 393
 SANDS, M. P., 329
 SANGER, D. J., 1013
 SATINDER, K. P., 707
 SATO, S. M., 915
 SAUMET, J.-L., 241
 SBORDONE, R. J., 63
 SCHALLERT, T., 455
 SCHECHTER, M. D., 1
 SCHENK, S., 841
 SCHMIDT, W. J., 677
 SCHNEIDER, D. R., 139
 SCHULZ, E. M., 697
 SCHUSTER, C. R., 347, 423, 851
 SCHWARTZ, R. D., 647
 SCLAFANI, A., 101, 293
 SEEGER, T. F., 119
 SHEARMAN, G. T., 249
 SHEPHARD, R. A., 741
 SHERMAN, A. D., 449
 SHOREY, R. A. L., 207
 SIBEL, M., 973, 979
 SILBERGELD, E. K., 285
 SIMLER, S., 57
 SIMMONS, W. H., 819
 SINDEN, J. D., 181
 SINGHAL, R. L., 229
 SIVIY, S. M., 173
 SLIFER, B. E., 683
 SMITH, C. C., 29
 SMITH, G. J., 805
 SMITH, J. E., 329, 509, 641
 SNOW, A. E., 47
 SPARBER, S. B., 621, 937
 SPEAR, L. P., 481, 805
 SPEAR, N. E., 805
 SPIRDUSO, W. W., 455
 SPYRAKI, C., 197
 STEINFELS, G. F., 167
 STERN, J. S., 627
 STEVENS, R., 93
 STOKES, P. E., 801
 STONE, W. S., 751
 STRAHLENDORF, H. K., 909
 STRAHLENDORF, J. C. R., 51, 909
 STRIPLING, J. S., 855
 STUTZ, R. M., 81
 SVIKIS, D. S., 113
 SZOSTAK, C., 67

TAKAGI, A., 311
TAKAHASHI, R., 311
TAKEDA, S., 315
TAKEMORI, A. E., 621
TALLMAN, J. F., 29
TAMAKI, Y., 943
TANAKA, M., 315, 637
TANG, M., 155
TAYLOR, A. N., 585
TAYLOR, K. M., 373
THEOTOKATOS, J. E., 757
THOMPSON, D. M., 159, 647
THOMPSON, T. I., 271
THURMOND, J. B., 73
TOBET, S. A., 211
TOMBAUGH, J. W., 67
TOMBAUGH, T. N., 67
TRIANA, E., 801
TRAYLOR, K. L., 565
TSUDA, A., 637
TUCKER, S. M., 47

UPCHURCH, M., 455
VADLAMANI, N. L., 847
VALDES, J. J., 915
VAN DER POEL, A. M., 41
VAUGHN, D., 455
VICKERS, G., 151
VILLIGER, J. W., 373
VOCCI, F. J., 441
VON ALMEN, T. K., 1017
VOORNEVELD, P., 67
WAGNER, B. H., 731
WALLER, M. B., 125, 501
WALLER, S. B., 441
WARREN, P. H., 869
WEBB, S. A., 521
WEISS, B., 761
WESTENBERG, I. S., 815
WHITE, K., 417

WILCOX, R. E., 455
WILSON, C. A., 777
WITTEN, M., 185
WISE, J., 777
WOOLVERTON, W. L., 491
WRIGHT, J. W., 697
WYATT, R. J., 429
YANAI, J., 235
YOCHMOWITZ, M. G., 605
YOSHIDA, H., 437
YOSHIMOTO, S., 311
YOUNG, G. A., 167
YOUNG, R., 553, 557
YUNGER, L. M., 737
XENAKIS, S., 293
ZENICK, H., 81

CURT P. RICHTER PRIZE IN PSYCHONEUROENDOCRINOLOGY

Through the generosity of the Irish Foundation for Human Development, an Annual Prize has been established for meritorious research in the area of Psychoneuroendocrinology. The sum of \$1,000 will be awarded annually for the best essay or manuscript (original research or a review including original research) submitted by a scientist or physician under 40 years of age by January 1, 1983. The winning paper will automatically be considered for publication in the journal, *Psychoneuroendocrinology* and should be prepared according to the journal's instructions to authors. The aim of the prize is to encourage younger scientists to contribute to this interdisciplinary field.

Manuscripts should be submitted in quadruplicate to:

Gerhard Langer, M.D.
Associate Professor of Psychiatry
Allgemeines Krankenhaus der Stadt Wien
Psychiatrische Universitätsklinik
Lazarettgasse 14
A-1097 Vienna
AUSTRIA

All submissions will be screened by a broad committee of established psychoneuroendocrinologists. Deadline January 2, 1983. The prize will be awarded at the 1983 meeting of the society in New York, N.Y., U.S.A. The winner will be notified by May 1, 1983.

CALL FOR PAPERS

Fourth Annual Winter Neuropeptide Conference

The Winter Neuropeptide Conference is designed to provide an informal setting for interactions between basic and clinical scientists studying behavioral, biochemical, and physiological actions of neuropeptides. The format includes short slide presentations and posters of original papers and symposium/workshop discussions of topics of broad general interest. Topics of interest include basic and applied research on behavioral effects of peptide neurotransmitters and/or neuromodulators, their biochemical and physiological actions on human and animal behaviors such as sensory-motor performance (human factors), attention, learning, affective state, memory, psychopathologies, etc.

The meeting will be held January 19-22, 1983, in Breckenridge, Colorado. A brief abstract of proposed presentation should be received by October 4, 1982. Abstracts and inquiries should be addressed to:

F. Robert Brush, Ph.D.
Department of Psychological Sciences
Purdue University
West Lafayette, IN 47097
(317) 494-6061

Papers accepted for presentation will be published in *Peptides*, subject to customary editorial review.

INTERNATIONAL SOCIETY FOR DEVELOPMENTAL PSYCHOBIOLOGY

1982 Annual Meeting

October 28-31

Minneapolis, Minnesota

For meeting information contact: William P. Smotherman, Ph.D.
ISDP Conference Organizer
Department of Psychology
Moreland Hall 204
Oregon State University
Corvallis, OR 97331